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ACTH adrenocorticotropic hormone 
anti-WoN  antibody against the N-terminus 
AR autosomal-recessive inheritance pattern 
BGC blood glucose concentration 
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Wfs1 Wolfram syndrome 1 related protein coded by Wfs1 gene in any 
species other than human 
Wfs1KO Wfs1 knock-out mice 
WS Wolfram syndrome 
WSD Wolfram syndrome related diabetes 
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Wolfram syndrome (WS), also known as DIDMOAD syndrome, was first 
described by Wolfram and Wagener in 1938. It is an autosomal recessive 
disorder usually diagnosed in childhood when non-autoimmune type I diabetes 
occurs with optic atrophy, cranial diabetes insipidus, and sensorineural deafness 
(Wolfram and Wagener, 1938; Barrett and Bundey, 1997; Smith et al., 2004). 
Other abnormalities related to this syndrome are dilated renal outflow tracts, 
multiple neurological abnormalities, and various neurological and psychiatric 
disorders (Peden et al., 1986; Barrett et al., 1995; Barrett and Bundey, 1997; 
Medlej et al., 2004). Wolfram syndrome is caused by a mutation in the WFS1 
gene on chromosome 4p16 (Collier et al., 1996). This gene is responsible for 
encoding wolframin, a glycoprotein of the endoplasmic reticulum, although the 
function of the wolframin protein is not fully understood (Hofmann et al., 2003; 
Fonseca et al., 2005; Riggs et al., 2005). There is growing evidence that Wfs1 
plays an important role in the pathogenesis of endoplasmic reticulum (ER) 
stress and apoptosis (Fonseca et al., 2005; Riggs et al., 2005; Yamada et al., 
2006).  
The exact mechanism of development of the diabetes related to WS is not 
yet known. Some data has shown that the onset of diabetes tends to occur 
earlier in boys than in girls (Barrett and Bundey, 1997; Hardy et al., 1999; 
Smith et al., 2004). The development of diabetes has been associated with 
increased ER stress and apoptosis in pancreatic beta cells, leading to insufficient 
insulin secretion (Ishihara et al., 2004; Riggs et al., 2005). However, no studies 
have measured the concentration of proinsulin, an insulin precursor, in plasma. 
Some data indicate that prohormone convertase 2 (PC2) is absent in some 
patients with WS, and disturbances in converting prohormones into biologically 
active forms (e.g. proinsulin to insulin) may therefore exist (Gabreels et al., 
1998). In addition, recent genetic association studies have also indicated the 
role of Wfs1 in the development of type 2 diabetes (Sandhu et al., 2007; Franks 
et al., 2008; Sparso et al., 2008), in which the leading mechanism in the 
development of diabetes is insulin resistance.  
There is data to suggest that one of the manifestations of WS is growth 
hormone deficiency (Barrett et al., 1995; Barrett and Bundey, 1997; Koks et al., 
2009), which is thought to be the reason for growth retardation in patients with 
WS, but there is a lack of longitudinal growth data that would describe the 
possible growth failure.  
As yet there has been no data regarding the fertility of patients with WS. 
Previous studies have described anterior pituitary dysfunction (Medlej et al., 
2004) and, in male patients, the presence of primary gonadal atrophy and 
hypergonadotropic hypogonadism (Peden et al., 1986; Barrett and Bundey, 
1997; Medlej et al., 2004). As far as we know, the role of the Wfs1 gene in 
fertility has not been studied.  
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There are some brief reports showing impaired thyroid function in patients 
with WS, but the incidence is not known (Tranebjaerg et al., 1993; Hildebrand 
et al., 2008; Yan et al., 2013). Most published cases lack information about 
thyroid function. The Wfs1 gene is highly expressed in the thyroid tissue of 
mice (Kõks S, 2008) and moderately in the thyroid tissue of adult humans (De 
Falco et al., 2012).  
The recent review paper by Cai et al. showed that many neurodegenerative 
diseases, such as Alzheimer’s, Parkinson’s, or Huntingdon’s disease, can affect 
the metabolism in these patients through different mechanisms, such as changes 
in weight, glucose metabolism, or leptin levels, etc. (Cai et al., 2012). Patients 
with WS, a disease that is also considered to be a neurodegenerative disorder, 
may therefore also have an increased risk for disturbed metabolism. To our best 
knowledge, there have been no studies about the energy metabolism in patients 
with WS or its animal model, Wfs1-deficient mice. 
Mice lacking the Wfs1 gene (Wfs1KO) were created at the Laboratory of 
Physiology, University of Tartu (Luuk et al., 2009). This animal model of WS 
is useful for studying the functions of various endocrine systems affected in 
WS, including fertility, energy metabolism, the development of diabetes, and 
other endocrine problems.  
The aims of our study were to determine whether the fertility of Wfs1KO 
male mice is reduced, and, if so, to explore possible reasons. We wanted to 
describe the development of diabetes and investigate the secretion of insulin 
and proinsulin in the organism instead of cell culture. In addition, we aimed to 
describe the development of possible growth failure, to study the reasons for 
that, and to investigate the energy metabolism of these mice.  
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2. REVIEW OF THE LITERATURE 
2.1. Wolfram syndrome 
Wolfram syndrome (WS; OMIM 222300) is a rare, autosomal recessive (AR), 
neurodegenerative and progressive disease first described by Wolfram and 
Wagener in 1938 (Wolfram and Wagener, 1938). The acronym “DIDMOAD” 
(diabetes insipidus, diabetes mellitus, optic atrophy and deafness) is frequently 
used to describe the clinical features of WS (Barrett and Bundey, 1997). 
Although cranial diabetes insipidus (DI), sensorineural hearing loss, renal tract, 
and neurological abnormalities are seen in the majority of patients, only 
juvenile-onset diabetes mellitus (DM) and bilateral optic atrophy (OA) are 
necessary to make the diagnosis (Barrett et al., 1995; Collier et al., 1996; 
Farmer et al., 2013).  
Insulin-dependent non-autoimmune diabetes usually occurs as the initial 
manifestation during the first decade of life (average 6 years). The onset of DM 
tends to occur earlier in boys than it does in girls (Barrett and Bundey, 1997; 
Hardy et al., 1999; Smith et al., 2004). Bilateral OA presents at an average age 
of 11 years (Barrett and Bundey, 1997; Rigoli et al., 2011). In the second 
decade of life, sensorineural deafness develops in two-thirds of the patients and 
also partial cranial DI that usually responds well to intranasal or oral 
desmopressin (Barrett and Bundey, 1997; Rigoli et al., 2011). Most of the renal 
tract abnormalities (incontinence, recurrent urinary infections, and neuropathic 
bladder) develop early in the third decade (Barrett and Bundey, 1997; Rigoli et 
al., 2011). Neurological symptoms (cerebellar ataxia, peripheral neuropathy, 
central apnea, hemiparesis) and psychiatric illnesses (depression, psychosis, 
organic brain syndrome) are present in the fourth decade of life (Swift et al., 
1990; Barrett and Bundey, 1997), although a recent study showed that early 
brain development is also affected (Hershey et al., 2012). Other complications 
include primary gonadal atrophy with reduced fertility (Barrett et al., 1995), 
gastrointestinal dysmotility causing constipation or diarrhea, and respiratory 
symptoms (central apneas) (Barrett and Bundey, 1997). Life span is calculated 
to be 30–40 years, and death usually occurs by respiratory failure due to 
respiratory centre atrophy or asphyxia by food aspiration (Barrett et al., 1995; 
de Heredia et al., 2013). Full characterisation of all clinical features of WS is 
difficult because the number of patients in the majority of reports is small 
(Ganie and Bhat, 2009). The largest cohort of patients with WS is described in 
the paper by de Heredia et al. (2013). Clinical features of 392 WS patients have 








Table 1. The clinical features of WS patients. Minimum, maximum, mean, median (2nd 
quartile), standard deviation (SD) and percentage of all patients (n=392) presenting the 
clinical feature indicated (Table modified from (de Heredia et al., 2013)). 













Diabetes mellitus 1 6 7.7 50 6.4 98.21% 
Optic atrophy 2 11 12.4 53 7.0 82.14% 
Diabetes insipidus 1.5 13 14.7 72 8.4 37.76% 
Hearing defects 1 14 15.4 60 9.1 48.21% 
Urological defects 1 20 20.0 46 9.7 19.39% 
Neurological defects 2 23 23.2 53 12.3 17.09% 
Deceased 10 27 29.8 48 11.4 7.40% 
 
Wolfram syndrome is rare, and the prevalence varies from 1 in 100,000 in 
North America (Fraser and Gunn, 1977) to around 1 in 770,000 individuals in 
the UK (Barrett and Bundey, 1997). According to the same nationwide study, 
the prevalence in children was found to be 1 in 500,000 and the carrier rate was 
estimated to be 1 in 354 individuals (Barrett and Bundey, 1997). The highest 
published prevalence of WS is 1 in 68,000 in Lebanon, which is probably due to 
the high rate of consanguinity in this region (Medlej et al., 2004). Studies of 
around 400 patients with WS have been published up to 2013 (de Heredia et al., 
2013). 
The cause of WS is mutation in the WFS1 gene that produces a protein 
called wolframin. This was discovered in 1998. The gene is mapped to human 
chromosome 4p16.1 and is comprised of 8 exons spanning 33.4 kb of genomic 
DNA (Inoue et al., 1998; Strom et al., 1998). Wolfram syndrome is a very 
heterogenic disease, with more than 200 known mutations in the WFS1 gene, 
which complicates the establishment of a clear genotype-phenotype correlation 
(de Heredia et al., 2013). In addition to WFS1, WS can be also caused by 
mutations in the CISD2 (also known as ZCD2) gene (Chen et al., 2010). This 
disease is called Wolfram syndrome type 2 (WS2). Mutations in the CISD2 
gene have been mapped to the chromosome 4q22–24 (Amr et al., 2007). 
Wolfram syndrome 2 is similar to WS characterised by juvenile-onset diabetes 
mellitus, optic atrophy, high-frequency sensorineural hearing loss, urinary tract 
dilatation, and hypergonadotropic hypogonadism (Tranebjaerg et al., 1993; El-
Shanti et al., 2000; al-Sheyyab et al., 2001; Amr et al., 2007). In addition, 
patients with WS2 may present with severe gastrointestinal ulceration and 
bleeding (Amr et al., 2007). Presence of diabetes insipidus has not been 
described in WS2 (Tranebjaerg et al., 1993). This thesis is purely about WS 
caused by mutations in the WFS1 gene, sometimes also called Wolfram 
syndrome type 1.  
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2.2. The clinical picture of Wolfram syndrome 
2.2.1. Diabetes 
Wolframin (WFS1), a product of the WFS1 gene, is highly expressed in the 
pancreas of humans (Inoue et al., 1998) as well as in rodents (Hofmann et al., 
2003; Fonseca et al., 2005; Kõks S, 2008). WFS1 possibly helps to fold a 
protein precursor of insulin (proinsulin) into the mature form of the hormone 
(Fonseca et al., 2005; Rigoli et al., 2011). The expression of WFS1 is much 
greater in pancreatic islet cells than in the exocrine cells. In addition to the  
β-cells where the expression of WFS1 is the highest, expression is also found in 
δ-cells (Hofmann et al., 2003; Fonseca et al., 2005). WFS1 deficiency leads to a 
progressive loss of β-cells, impaired glucose tolerance, and cell cycle 
progression, accompanied by the activation of unfolded protein response 
pathways and higher susceptibility to apoptosis through endoplasmic reticulum 
(ER) stress (Ishihara et al., 2004; Riggs et al., 2005; Yamada et al., 2006; 
Rigoli et al., 2011). The reason for WS-related diabetes (WSD) is thought to be 
due to the insulinopenia that is secondary to the degeneration of the β-cells 
(Medlej et al., 2004). Post-mortem reports have shown selective loss of β-cells 
(Karasik et al., 1989). Animal studies also suggest possible defective insulin 
secretion in addition to β-cell loss (Ishihara et al., 2004).  
Diabetes is usually the first manifestation that occurs in patients. Studies on 
a large cohort of WS patients indicate that the average onset of WSD tends to 
be at 6 years (Barrett et al., 1995; Kinsley et al., 1995; Medlej et al., 2004). 
Rohayem et al (2011) has shown that WSD tends to occur significantly earlier 
than type 1 diabetes (DM1) (5.4 vs. 7.9 years respectively, p<0.001) (Rohayem 
et al., 2011). There is strong evidence that the onset of WSD tends to occur 
earlier in boys than it does in girls (Hardy et al., 1999; Smith et al., 2004; 
Marshall et al., 2013). The course of WSD tends to be milder than in DM1, 
with less microvascular complications. Patients with WS rarely develop 
ketoacidosis and they have lower daily insulin requirements and lower 
haemoglobin A1c (HbA1c) compared to patients with DM1, indicating better 
glycaemic control in WSD (Peden et al., 1986; Barrett et al., 1995; Kinsley et 
al., 1995; Cano et al., 2007a). Patients with WSD have shown remarkably long 
partial remission periods (>8 years) and measurable C-peptide levels, even 8 
years after the onset of diabetes (Fishman and Ehrlich, 1986; Rohayem et al., 
2011). However, after patients with WSD have started insulin treatment, the 
risk for severe hypoglycaemia increases and remains significantly higher than in 
patients with DM1 (37% vs. 7.9%, p<0.001) (Rohayem et al., 2011). DM1 
related autoantibodies are almost never detectable in diabetic patients with WS 
(Kumar, 2010). The main clinical differences distinguishing the diabetes in WS 





Table 2. Differences between WS and type 1 DM (Modified from (Kumar, 2010)).  
Characteristic WS Type 1 DM 
–  Ketoacidosis at 
presentationa 
3% 30% 
–  Insulin requirementb Satisfactory control with 
less intensive regimen 
Intensive regimen 
–  Other features of WS Yes No 
–  HLA subtyped HLA-DR2 (44.4%) Mainly HLA-DR3 and 
HLA-DR4 (HLA-DR2 in 
only 6.77%) 
–  Presence of antibodies  Rare reportsg 93%c 
–  Coarse of complications 
influenced by glycaemic 
controla 
No Yes 
–  Diabetic retinopathy 
(after 15 years)b 
35% 90% 
–  Diabetic nephropathyb 8% 27% 
–  Median age of death 30 yearsa 50 yearse 
–  Cause of deatha Neurological disorder, 
urological abnormalities, 
infection 
Myocardial infarction or 
coronary artery disease 
–  Recurrence risk in next 
pregnancy 
AR inheritance: 25% 3–6%f 
aKinsley BT et al. (Kinsley et al., 1995) 
bCano A et al. (Cano et al., 2007a) 
cGlastras SJ et al. (Glastras et al., 2005) 
dVendrell J et al. (Vendrell et al., 1994) 
eRaymond NT et al. (Raymond et al., 1995) 
fNelson Textbook of Pediatrics (Alemzadeh R, 2007) 
gNakamura A et al. (Nakamura et al., 2006) 
 
Many relatives of WS patients have diabetes (Fraser and Gunn, 1977), which 
suggests that the heterozygote carriers of WFS1 may contribute to the genetic 
heterogeneity of diabetes (Barrett, 2001). Ohata et al. (1998) has also presented 
a large Japanese family with WS, and showed that the obligate carriers of WFS1 
had increased risk of DM (Ohata et al., 1998).  
 
 
2.2.2. Optic atrophy 
Generalised OA usually presents in all patients at the time of diagnosis of WS, 
but is rarely the presenting finding. However, there are some reports where OA 
presented before WSD (Chaussenot et al., 2011). In Wolfram's original 
description, the two eldest siblings out of four developed poor vision at 6 and 8 
17 
years, respectively, and when examined 10 years later, acuity was reduced to 
the level where they could count only fingers (Wolfram and Wagener, 1938; 
Barrett et al., 1997). The median age for presentation of OA is shown to be 11 
years (range of 6 weeks to 19 years) (Barrett et al., 1995). The presenting 
symptoms are decreasing visual acuity and loss of colour vision. Patients 
typically complain that “everything started to go grey” (Barrett et al., 1997). It 
is shown that the loss of colour vision can be present and noticeable for patients 
long before the diagnosis of OA is made (median age for vision problems is 6 
years) (Marshall et al., 2013). Optic atrophy leads to perception of light and 
dark only, over a median of 8 years’ duration (Barrett et al., 1997).  
The natural history and pathogenesis of OA in WS remain unclear so far. 
Magnetic resonance imaging (MRI) scans in 2 patients have shown widespread 
atrophic changes throughout the brain, including the cerebellum, optic nerves, 
and chiasm (Rando et al., 1992). A few experimental studies have demonstrated 
that WFS1 is primarily localised in the retinal ganglion cells and in different 
cells of the optic nerve: in the inner nuclear layer, photoreceptors, and glial cells 
(Yamamoto et al., 2006; Kawano et al., 2008; Schmidt-Kastner et al., 2009; 
Rigoli et al., 2011). This could indicate that dysfunction of the WFS1 in the ER 
or in the cell body can lead to optic nerve atrophy through deficits in protein 
synthesis and axonal transport (Rigoli et al., 2011).  
Other ophthalmologic findings reported in WS, but yet not confirmed as part 
of the phenotype, are cataracts (Hansen et al., 2005), pigmentary retinopathy 




Sensorineural deafness, mostly high frequency deafness (HFD), is usually 
thought to be the third manifestation that occurs in patients with WS during the 
second decade of life. A recent large overview of 392 patients with WS patients 
shows that in almost 50% of them HFD appeared as the fourth or fifth clinical 
manifestation (29% and 19.4%, respectively) (de Heredia et al., 2013). 
Deafness is present in about 66% of individuals with WS. Deafness can present 
as a congenital form or progressively developing hearing impairment, while this 
sometimes may be mild (Tranebjaerg et al., 1993). Median age of onset is 12.5 
years (Barrett et al., 1995). It is suggested that females with WS more 
frequently have hearing impairment than males (Pennings et al., 2004) whereas 
Plantinga et al. did not find such a sex-related difference (Plantinga et al., 
2008). 
According to the audiograms, hearing loss is slowly progressive and 
involves mostly the high frequencies (Pennings et al., 2004; Plantinga et al., 
2008). 
WFS1 is expressed in different cochlear cells, such as in inner and outer hair 
cells, lateral wall cells, spiral ganglion and vestibule cells, as well as in many 
supporting cells (Cryns et al., 2003; Rigoli et al., 2011). It is suggested that 
5
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WFS1 helps to maintain proper levels of calcium ions in the inner ear that are 
essential for hearing (Cryns et al., 2003).  
It is unknown why hearing loss occurs at a high frequency in WS and at a 
low frequency in another disease related to Wfs1. The latter is called WFS1-




2.2.4. Diabetes insipidus 
Central DI usually develops in the second decade of life, and is thought to arise 
as a result of disturbed processing of the vasopressin precursor (Gabreels et al., 
1998). The other mechanism suggested for developing DI is the degeneration of 
the supraoptic and paraventricular nuclei (Scolding et al., 1996). It is shown 
that WFS1 is highly expressed in the human hypothalamus and moderately in 
the mouse hypothalamus (Kõks S, 2008). Kawano et al. showed that in mouse 
supraoptic and paraventricular nuclei, Wfs1 mRNA expression is relatively and 
constantly high during intrauterine development, but relatively low in postnatal 
life (Kawano et al., 2009).  
Neuroradiological and post-mortem reports of WS patients have shown an 
absence of normal T1 hyperintensity (so called bright spot) seen in the posterior 
pituitary lobe, a typical finding for central DI, along with gliosis and atrophy of 
the paraventricular and supraoptic nuclei of the hypothalamus (Galluzzi et al., 
1999; Pakdemirli et al., 2005; Ito et al., 2007; Boutzios et al., 2011).  
The prevalence of DI varies between 37% and 87%, depending on the 
studies of different patient cohorts (Barrett et al., 1995; Kinsley et al., 1995; 
Medlej et al., 2004; de Heredia et al., 2013; Marshall et al., 2013). The average 
onset of DI for WS patients is shown to be from 10.5 (Marshall et al., 2013) to 
14 years (Barrett et al., 1995). It seems that similarly with WSD, DI tends to 
occur earlier in male patients than in females (Marshall et al., 2013). Central DI 
in WS responds well to vasopressin treatment (Barrett and Bundey, 1997; Smith 
et al., 2004) 
 
 
2.2.5. Neurological and psychiatric symptoms 
Neurological and psychiatric complications are common in patients with WS. 
They present in 62% of patients and at a median age of 30 years (Barrett et al., 
1995). There are some studies that indicate that the onset of neurological 
symptoms occurs much earlier – between the first and second decade of life 
(Tranebjaerg et al., 1993; Chaussenot et al., 2011).  
WFS1 is highly expressed in different parts of the brain in humans, as well 
as in rodents. In rats a high expression of Wfs1 mRNA and protein in some 
areas of the limbic system, such as the amygdala, hippocampal region, olfactory 
tubercle, and superficial layer of the preform allocortex, has been shown 
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(Takeda et al., 2001). In mice, Wfs1 expression is highest in the amygdala, 
followed by the cerebral cortex, frontal cortex, dorsal striatum, and 
hippocampus. In humans WFS1 expression in the brain and the parts of the 
brain is also higher than the average, with the highest levels in the prefrontal 
cortex, amygdala, caudate nucleus, hypothalamus, and thalamus (Kõks S, 
2008). 
Common neurological manifestations of WS patients are truncal ataxia 
causing unsteady gait and falls, startle myoclonus, reduced limb reflexes, 
nystagmus, dysarthria, central apnoea, loss of taste and smell, hemiparesis, loss 
of gag reflex, epilepsy, and neurogenic bladder (Cremers et al., 1977; Rando et 
al., 1992; Barrett et al., 1995; Scolding et al., 1996; Barrett and Bundey, 1997; 
Baz et al., 1999; Medlej et al., 2004). Neurological findings are progressive and 
result from general brain atrophy with brain stem and cranial nerve involvement 
(Barrett and Bundey, 1997; Pakdemirli et al., 2005; Domenech et al., 2006). 
MRI can show generalised brain atrophy that is most prominent in the 
cerebellum, medulla, and pons. In addition, reduced signal intensity of the optic 
nerves and the posterior part of the hypothalamus is seen (Barrett et al., 1995). 
The correlation between the MRI findings and clinical picture is not always 
strong (Ito et al., 2007). A recent study by Hershey et al. (2012) demonstrates 
abnormalities in the brainstem and cerebellum already in young patients that 
could indicate that WFS1 also affects brain development and not only the later 
neurodegeneration (Hershey et al., 2012). 
25% of WS patients seem to be affected by episodes of severe depression, 
psychosis, as well as aggression. There is also a trend for patients with WS to 
show a higher suicide rate (Swift et al., 1990; Sequeira et al., 2003; Rigoli et 
al., 2011). Swift et al. (1998) have suggested that the prevalence of WFS1 
heterozygous carriers is approximately 1% in the general population, and the 
carriers have a 7-fold increased risk of hospitalisation for psychiatric diseases 
(Swift et al., 1998).  
 
 
2.2.6. Reproductive system 
Studies of reproductive function in patients with WS are currently lacking. 
Some patients are affected by anterior pituitary dysfunction. In male patients the 
presence of gonadal atrophy, as well as hypergonadotropic or hypogonadotropic 
hypogonadism have been described (Cremers et al., 1977; Homan and MacKay, 
1987; Barrett et al., 1995; Barrett and Bundey, 1997; Simsek et al., 2003; 
Medlej et al., 2004; Rigoli et al., 2011). In 2013, Haghighi et al. first described 
two male patients from one family carrying a novel mutation (p.Asp211Asn, 
p.Gln486*) who had been able to father children (Haghighi et al., 2013). In 
females ovarian function seems to be normal, only with abnormalities in the 
menstruation cycle (Medlej et al., 2004), and successful pregnancies with 
unaffected children have been reported (Davidson et al., 1993). 
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WFS1 is highly expressed in human reproductive organs: expression is 
highest in the testes, particularly in germ cells, but also in the prostate and 
uterus. In mice the expression rate of Wfs1 in reproductive organs is mild, with 
the highest expression in ovaries and uterus, followed by lower expression in 
the testes and prostate (Kõks S, 2008). 
According to present knowledge, the role of the Wfs1 gene in fertility in WS 




Short stature is quite common in patients with WS (Hofmann et al., 1997a; 
Simsek et al., 2003; Medlej et al., 2004; Ganie et al., 2011). Medlej et al. 
(2004) reported pituitary dysfunction in their study of Lebanese patients with 
WS, probably of hypothalamic origin. The most common abnormality in this 
study was growth hormone (GH) deficiency, followed by adrenocorticotropic 
hormone (ACTH) deficiency (Medlej et al., 2004). Soliman et al. (1995) 
reported two girls with isolated GH deficiency and short stature (Soliman et al., 
1995).  
Despite the fact that short stature is common in patients with WS, the exact 
mechanism for impaired growth remains unclear.  
 
 
2.2.8. Energy metabolism and thyroid function 
There is no data about the energy metabolism of patients with WS. There are 
only a few studies showing impaired thyroid function in patients with WS 
(Smith et al., 2004; Hildebrand et al., 2008; Yan et al., 2013), but the incidence 
of this problem is not known (Tranebjaerg et al., 1993). The Wfs1 gene is 
highly expressed in the thyroid tissue of mice (Kõks S, 2008), and moderately 
in the thyroid tissue of adult humans (De Falco et al., 2012). 
 
 
2.3. WFS1 gene and it’s protein wolframin 
Wolfram syndrome was initially thought to be caused by mitochondrial 
mutations, but these have been reported only in some very few cases (Bundey et 
al., 1992; Rotig et al., 1993; Barrientos et al., 1996; Hofmann et al., 1997b). In 
1998 a nuclear gene for WS, WFS1, was discovered and mapped to 
chromosome 4.16.1 by linkage studies (Inoue et al., 1998; Strom et al., 1998).  
In humans the WFS1 gene is located in the short arm of the 4th chromosome 
(4p16.1) and in mice on the long arm of the 5th chromosome (5qB3). There is an 
83% overlap in the nucleotide sequence of the WFS1 gene and 87% overlap in 
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the amino acid sequence of its protein wolframin in humans and mice (Strom et 
al., 1998).  
WFS1 has eight exons; the first exon is noncoding and comprises 33.4 kbp 
on chromosome 4p16.1 (Inoue et al., 1998). The 8th exon is the largest (2.8 kb), 
containing about 60% of the whole protein-coding sequence of the WFS1 gene, 
and the majority of the mutations described in WS are located in this exon 
(Cryns et al., 2003).  
 
 
Figure 1. Structure of the WFS1 gene (http://genome.ucsc.edu ). 
 
WFS1 encodes the 890-amino-acid protein called wolframin. The protein has 
nine transmembrane segments across the ER membrane and an Ncytoplasm/CER lumen 
membrane topology that forms homomeric complexes of 400 kDa under 
physiological conditions (Inoue et al., 1998; Takeda et al., 2001; Hofmann et 
al., 2003).  
  
2.3.1. WFS1 functions  
The exact function of wolframin (Wfs1) is not known. It seems to have a 
significant role in the transportation of proteins, lipids, and many other 
materials – particularly Ca2+ ions – into different parts of the cell by the 
endoplasmic reticulum (Osman et al., 2003; Yamada et al., 2006). Mutations in 
the WFS1 gene lead to the production of a wolframin protein that has reduced or 
absent function. This leads to a case in which calcium levels within cells are not 
properly regulated, and to the development of dysfunction of the endoplasmic 
reticulum (ER). Wolframin is localised in ER, where it is folded and modified 
to obtain the necessary structure for normal functioning. Wolframin seems to 
modulate Ca2+ the endoplasmic reticulum does not have enough functional 
wolframin, it causes ER stress, impairs cell cycle progression, and triggers the 
apoptotic pathway, most likely through impairment of Ca2+ homeostasis 
(Collier, 2008). Depending on the cells, it leads to the development of different 
clinical features of WS. 
Studies of Wfs1-deficient pancreatic β-cells have shown impairments of 
glucose-stimulated insulin secretion and cell cycle progression by activation of 
ER stress/unfolded protein response (UPR) pathways and enhanced 
susceptibility to apoptosis (Ishihara et al., 2004; Riggs et al., 2005; Yamada et 
al., 2006). WFS1 appears also to have a function in the survival of neurons 
(Gharanei et al., 2013).  
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Early studies on the role of the Wfs1 gene in the development of diabetes 
focused mostly on beta cell survival (Sandhu et al., 2007). Normal Wfs1 seems 
to protect beta cells, as mice with a disrupted Wfs1 gene exhibit beta cell loss 
(Yamada et al., 2006). This phenotype has been thought to result from the 
activation of ER stress (Ueda et al., 2005). ER stress is the response to the 
overload in ER luminal conditions (e.g. increased secretory activity). ER stress 
activates a signalling cascade that attempts to restore a favourable folding 
environment. The activated response is UPR. UPR is a molecular transduction 
system that monitors the protein folding capacity of the ER and signals cell 
responses that attempt to maintain folding capacity and prevent a build-up of 
unproductive and potentially toxic protein products (transient inhibition of 
protein synthesis, etc.). If UPR is not sufficient to deal with the stress 
conditions, apoptotic cell death is initiated (Lai et al., 2007). The UPR consists 
of three main signaling systems initiated by three prototypical ER localized 
stress sensors – IRE1, PERK, and ATF6. The Wfs1 protein has proven to be 
related to the IRE1 and PERK pathways (Kakiuchi et al., 2006; Yamada et al., 
2006). Wfs1 induces expression of XBP1 (X-box-binding protein 1), which is 
the major initiator for UPR target genes (binds to the ER stress response 
element) (Kakiuchi et al., 2006; Yamada et al., 2006). While it is clear that the 
Wfs1 protein is closely related to ER stress and increased expression of Wfs1 
protects cells from ER-stress-induced death, the molecular mechanism of this 
action is not at all clear (Yamada et al., 2006).  
Taking into consideration the most common symptoms of WS patients, 
pancreatic β-cells and neurons seem to be most affected from the loss of WFS1 
function.    
2.3.2. Wfs1 expression 
The first information concerning expression of the Wfs1 gene comes from the 
cloning studies by Inoue et al. and Strom et al. (Inoue et al., 1998; Strom et al., 
1998). In 1998, Inoue and his colleagues performed Northern blot from the 
panel of RNA of adult human tissues and found WFS1 expression in basically 
all analysed tissues (heart, brain, placenta, lung, liver, skeletal muscle, kidney, 
and pancreas). The expression was equally strong in all studied tissues with the 
weakest signals from the liver and skeletal muscle. The exocrine tissue of the 
pancreas had a weaker signal than the islets (Inoue et al., 1998; Kõks S, 2008). 
Strom et al. analysed the tissue distribution of the WFS1 gene. They found the 
strongest signal in the heart, followed by the brain, placenta, lung, and pancreas. 
Weak signal was present in the liver, skeletal muscle, and kidney (Strom et al., 
1998; Kõks S, 2008). Thus, the very first studies already showed that WFS1 has 
a very widespread expression in the human organism, which probably explains 
the very variable clinical picture of WS.  
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Hofmann et al. studied the distribution of Wfs1 with immunohistochemical 
methods analysing Wfs1 expression in different mouse tissues (Hofmann et al., 
2003). In their study, Wfs1 was expressed in all tissues studied. The highest 
expression levels were found in the brain, pancreas, heart, and muscle; followed 
by the liver, the lowest levels were seen in the kidneys and spleen. Analysis of 
different mammalian cell lines with anti-WoN antibodies revealed the highest 
expression in insulinoma cells and much lower expression in human fibroblasts 
and neuroblastoma cells (Hofmann et al., 2003; Kõks S, 2008). 
The primary focus of attention in Wfs1 protein research has been on its 
function in different parts of the brain, in pancreas islet cells, and in different 
cells of the eyes and ears. This is not surprising, because different brain regions, 
as well as the pancreas, eyes, and ears, express Wfs1 protein in high levels and 
are the main affected organs in WS. In the mouse brain, the Wfs1 gene 
expression level is higher in brain structures related to emotions, learning, and 
memory (Luuk et al., 2008): very strong expression of Wfs1 is detectable in the 
central extended amygdala and ventral striatum, followed by the hippocampal 
region, prefrontal cortex, and proisocortical areas.  
Strong Wfs1 expression has been evident in the retina and in the optic nerve 
(Yamamoto et al., 2006). Several studies suggest that mutation in the Wfs1 gene 
can influence survival and function of both retinal ganglion cells and glial cells 
in the optic nerve (Takeda et al., 2001; Yamamoto et al., 2006; Kõks S, 2008). 
WFS1 is expressed in different cochlear cells, such as in the inner and outer hair 
cells, lateral wall cells, spiral ganglion, and vestibule cells, but also in many 
supporting cells (Cryns et al., 2003; Rigoli et al., 2011). It is suggested that 
WFS1 helps to maintain proper levels of calcium ions in the inner ear that are 
essential for hearing (Cryns et al., 2003; Kõks S, 2008).  
 
 
2.3.3. Mutations of WFS1 in Wolfram syndrome 
Genetic analyses in patients with WS have identified a wide spectrum of 
mutations in the WFS1 gene (Tranebjaerg et al., 1993; Inoue et al., 1998; Strom 
et al., 1998; Hardy et al., 1999; Khanim et al., 2001; Cryns et al., 2003; Smith 
et al., 2004; Hansen et al., 2005; Cano et al., 2007b; Hildebrand et al., 2008; de 
Heredia et al., 2013). In WS patients the mutations in the WFS1 gene are 
distributed across the length of the coding region in exon 8, and include 
deletions, insertions, nonsense, and missense mutations (Khanim et al., 2001). 
Mutations in WFS1 are deleterious for protein expression (Hofmann et al., 
2003; Guo et al., 2011; de Heredia et al., 2013). Glycosylation sites are 
identified as being important for protein stability (Hofmann et al., 2003). A 
region that targets unfolded WFS1 to degradation (degron) has also been found 
(Guo et al., 2011; de Heredia et al., 2013). Many of the missense mutations are 
located in the C-terminal hydrophilic part of the protein (Hardy et al., 1999). 
More than 200 variations in WFS1 have been described in patients with WS, 
24 
which complicates the establishment of clear phenotypic-genotypic correlation 
(de Heredia et al., 2013).  
De Heredia and his colleagues have recently published a comprehensive 
review of all published mutations of WFS1 in the last 15 years (de Heredia et 
al., 2013). To ease the phenotype-genotype correlations, the mutations were 
classified into different types based on their predicted effect on WFS1 
expression. Accordingly, three types of mutations were determined. Type I 
mutations lead to complete depletion of the WFS1 protein due to the activation 
of nonsense-mediated decay, including nonsense and frameshift mutations 
producing stop codons before exon 8. Type II includes mutations that lead to 
complete degradation of WFS1 by keeping the degron of WFS1 functional. This 
group includes all missense mutations except those between amino acids 671–
700, and those nonsense mutations producing a stop codon after p.Trp700. The 
third group, type III, includes mutations leading to the expression of a defective 
or shorter WFS1 protein. In this group are nonsense mutations that introduce a 
stop codon after exon 8 and before p.Trp700, frameshift mutations introducing 
a stop codon after exon 8, and missense mutations in amino acids 671–700 (de 
Heredia et al., 2013).  
De Heredia et al. detected 178 different mutations in 337 patients. The 
mutations are distributed all along the protein with no major hotspots. They 
concentrate mainly in transmembrane domains and glycosylation sites. Only six 
mutations were present in more than 5% of patients: c.2649delC 
(p.Phe884Serfs*68), c.1230_1233del (p.Val412Serfs*29), c.409_424dup 
(p.Val142Glyfs*110), c.2119G→A (p.Val707Ile), c.1362_1377del (p.Tyr454*), 
and c.1243_1245del (p.Val415del). According to the above-mentioned 
classification, 5.62% of the mutations were assigned to type I, 55.6% to type II, 
and 38.2% to type III (de Heredia et al., 2013).  
To study whether different mutation types have a role in the earlier onset of 
the clinical features, de Heredia et al. classified the patients into different 
classes by their genotype. Class A includes genotypes where no WFS1 protein 
was produced. This class was further subdivided into three subclasses by the 
mechanism of WFS1 depletion: subclass A1 due to WFS1 mRNA degradation, 
subclass A2 due to mRNA and protein degradation, and subclass A3 due to 
WFS1 protein degradation. Class B includes genotypes with reduced expression 
of a defective WFS1 protein and class C those with expression of a defective 
WFS1 protein. Out of 337 patients, there were 51.9% in class A, 19% in class 
B, and 29.1% in class C. The distribution of the genotypes differed between the 
countries. Patients in class C showed earlier onset of most clinical features of 
WS. Patients in class A1 had earlier onset of DM, in contrast to patients in class 
A2 who developed earlier DI and OA. The progression rate showed to be faster 




Figure 2. Mutations distribution in WFS1 (figure from de Heredia et. al 2013 with 
permission) 
a) Mutation position. Position and type of each mutation are shown in a schematic 
model of WFS1 protein. The position of the degron (amino acids 671–700), the first 
amino acid encoded by exon 8 (p.Lys287), the two glycosylation sites and amino 
acid positions at ER membrane contents are indicated. Amino acid positions can 
have more than one mutation and have a different color only if affected by different 
mutation types. Color code identifies mutation types at that amino acid position: 
blue – type I mutation, red – type II, green – type III, cyan – type II or III, yellow – 
type I or II.  
b) Mutation distribution. The number of mutations is calculated for a 10-amino-acid 
sliding window along the protein. White boxes below the chart indicate windows 
including the transmembrane domains; blue box indicates windows including the 
degron. Glycosylation sites are also indicated at their approximated locations (de 
Heredia et al., 2013). 
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2.3.4. WFS1 and other diseases 
There appear to be several diseases that are related to the different mutations in 
the WFS1 gene. Some case series have reported a higher prevalence of DM, 
sensorineural hearing loss, or psychiatric disorders among the relatives of WS 
patients (Scolding et al., 1996; Ohata et al., 1998; Swift et al., 1998).  
Several investigators have found that mutations in the WFS1 gene are a 
common cause of autosomal dominant low-frequency sensorineural hearing loss 
(LFSNHL) (Bespalova et al., 2001; Young et al., 2001; Cryns et al., 2003; 
Fukuoka et al., 2007). This is remarkable because in WS the hearing loss is 
mostly at high frequencies (Collier, 2008). With few exceptions, all mutations 
causing LFSNHL are located in the fifth intracellular domain, whereas hearing 
loss in WS is mostly due to inactivating mutations that are spread throughout 
the entire coding region of the WFS1 gene (Cryns et al., 2003; Collier, 2008).  
WFS1 has also been associated with diabetes mellitus (Sandhu et al., 2007; 
Collier, 2008). Sandhu et al. (2007) included WFS1 in a panel of 84 genes 
related to β-cell function, and found a positive association with WFS1 SNPs in 
three type 2 diabetes populations from the UK, and one of Ashkenazi Jews. 
This indicates that WFS1 appears to be a significant genetic cause of type 2 
diabetes (Sandhu et al., 2007; Collier, 2008). Genome-wide association (GWA) 
studies have shown that heterozygote mutations of WFS1 have also been related 
to DM2 (Cheng et al., 2013). In the case of DM1 the data is ambivalent: earlier 
studies have linked a DM1 locus in the region of WFS1 (Larsen et al., 2004) 
and pointed out also some polymorphisms in WFS1 that could be related to the 
DM1 (Awata et al., 2000). Later studies have not found any association 
between WS and DM1 (Collier, 2008). 
Heterozygote carriers of WFS1 gene mutations, mainly the first line relatives 
of WS patients, are supposed to be at increased risk for psychiatric disease and 
suicidality, and need frequent hospitalisation due to psychiatric problems (Swift 
et al., 1998) 
  
2.4. Wfs1-deficient mouse models 
To study the role of Wfs1, several mouse models of Wfs1 deficiency have been 
created. So far, three different Wfs1-deficient mouse models have been 
independently developed by different research groups, one of them by the 
scientists from the University of Tartu, Estonia.  
 
 
2.4.1. Japanese model (Ishihara group) 
The first Wfs1-deficient mouse model reported in the literature was created by 
Ishihara and colleagues in 2004 (Ishihara et al., 2004). Their mouse model is a 
so-called “full knock-out” mode; namely, exon 2 of the Wfs1 gene has been 
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deleted in these mice. It is important that Wfs1 mRNA is still detectable in these 
mice. The mice were normal in appearance, growth, and fertility and showed 
distribution by Mendelian genotypic rules. Studies showed that these mice had 
decreased insulin secretion and high blood sugar levels in response to the 
glucose tolerance test. Progressive loss of pancreatic β-cells that was caused by 
apoptosis and ER stress resulting in severe impairment of glucose homeostasis 
was shown only in the 129SVEV x C57BL/6 F2 genetic background. The 
findings were more severe in male mice compared to female mice. While the 
mice were backcrossed to the C57BL/6 F5 background, the overt diabetes was 
no longer present. This finding indicates that this background protects mice 
against diabetes in the case of Wfs1 deficiency. To reduce the phenotypic 
variations, only F5 generation males were used in further experiments (Ishihara 
et al., 2004).  
 In the other study, Kato and colleagues used the same mice in the 
behavioural experiments (Kato et al., 2008). All the mice they used were males 
backcrossed to the C57BL/6 background for at least 8 generations. The most 
notable finding was that the homozygous Wfs1-deficient mice displayed an 
overall tendency for lower social interaction. The results support the impression 
that Wfs1-deficient mice have subtle impairments in behavioural activation in 
demanding situations (Kato et al., 2008). 
 
 
2.4.2. University of California model (Riggs group) 
The second model was created in 2005 by Riggs and colleagues (Riggs et al., 
2005). Their model is a conditional Wfs1 exon 8 knock-out mouse. The mice 
are in the 129SVJ genetic background with a pancreatic-specific deletion of 
exon 8 of the Wfs1 gene. The mice are reported to be fertile and distributed by 
Mendelian rules (Riggs et al., 2005). These male mice are used in glucose 
metabolism investigations and are shown to develop progressive glucose 
intolerance, insulin deficiency, and DM2-like features by 4 months of age. 
Their body weight is significantly lower than in wild-type controls. The 
findings of Riggs et al. show that these mice have a significantly smaller mass 
of insulin-producing pancreatic β-cells, which is caused by increased apoptosis 
and ER stress. Most of the disturbances became significantly evident by the age 
of 6 months (Riggs et al., 2005). In relation to the mice investigated by Ishihara 




2.4.3. The University of Tartu model (Kõks group) 
The third model of Wfs1-deficient mice was generated at the University of 
Tartu in 2005. In these conventional Wfs1 knock-out mice, exon 8 in the Wfs1 
has been deleted. Wfs1-deficient mice were generated by targeting construct to 
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replace most of the coding region of the Wfs1 gene in all tissues. This is 
different from the Riggs model, where Wfs1 was deleted only in the pancreas. 
A more detailed description of the methodology for generating this animal 
model is given in the Methods section.  
The rationale behind the strategy for generating Wfs1 mutant mice at the 
University of Tartu was to delete the majority of the coding sequence forming 
the mouse genome. This approach ensures that Wfs1 protein is not being 
produced or only a truncated form is produced. We deleted 2/3 of the protein 
coding sequence and fused it with the lacZ gene. New fusion protein is easily 
detectable in histochemical analysis and we used this mouse for detailed 
expression mapping of the Wfs1 gene. Moreover, when comparing our animal 
data to the animal data from other labs, we can conclude that our animals have a 
more severe phenotype than mutant mice developed by others. Taken together, 
the Wfs1 mutant mouse we developed is a more precise model for Wolfram 
syndrome than the model developed in other labs. 
Before our work, these mice were mainly used to describe the behavioural 




3. AIMS OF THE STUDY 
1. To determine whether the fertility of Wfs1-deficient (Wfs1KO) male mice is 
reduced and, if so, to explore the possible reasons  
2. To compare the morphology of testes and sperm between Wfs1KO and wt 
mice 
3. To investigate the sex differences in longitudinal changes of blood glucose 
concentration and weight of Wfs1KO mice.  
4. To compare plasma proinsulin and insulin levels between Wfs1KO and wt 
mice 




4. MATERIALS AND METHODS 
4.1. Animals 
In accordance with the European Communities Directive (86/609/EEC), the 
Estonian National Board of Animal Experiments granted permission (No. 86, 
28.08. 2007) for the animal experiments described in this study. Mice were 
housed under standard laboratory conditions on a 12-hour light/dark cycle 
(lights on at 07:00 hours) with free access to food and water.  
In all the experiments the Wfs1KO mice and their wt littermates were used. 
The mice were generated by targeting construct to replace most of the coding 
region of the Wfs1 gene (Figure 3). For that the 8.8 kb BamHI restriction 
fragment from the PAC clone 391-J24 (RPCI21 library, MRC UK HGMP 
Resource Centre, UK) was subcloned into a pGem11 cloning plasmid 
(Promega, Madison, WI). The 3.7-kb NcoI fragment was replaced with an in-
frame NLS-LacZ-Neo cassette. This resulted in the deletion of amino acids 
360–890 in the Wfs1 protein and a fusion between the Wfs1 1–360 fragment 
and LacZ. This construct was inserted into W4/129S6 embryonic stem (ES) 
cells (Taconic, Hudson, NY) at the Biocenter of the University of Oulu 
(http://www.biocenter.oulu.fi). Colonies resistant to G418 and ganciclovir were 
screened for homologous recombination by polymerase chain reaction (PCR) by 
using the recombination-specific primers NeoR1 5’GACCGCTATCAGGACA 
TAGCG3’ and Wfs1_WTR1 5’AGGACTCAGGTTCTGCCTCA3’. The PCR 
product was sequenced to verify that homologous recombination took place, 
and injected ES clone 8A2 into C57BL/6 blastocysts. The invalidation of Wfs1 
gene was verified by mRNA expression analysis and we confirmed the lack of 
Wfs1 transcript in homozygous Wfs1 mutant mice (Koks et al., 2009).  
According to the Mouse Genome Database (http://www.informatics.jax.org/), 
the official designation of this strain is Wfs1tm1Koks. In order to avoid the 
“congenic footprint” effect (Schalkwyk et al., 2007) the animals were bred into 





Figure 3. The strategy of making Wfs1 knock-out mouse. Exon 8 in the Wfs1 gene was 
replaced with NLS-LacZ-Neo expression cassette (Luuk et al., 2008) 
 
 
4.1.1. Fertility in Wfs1KO male mice (Paper 1) 
In the fertility study we used 13 Wfs1KO, 13 wild type (wt) male mice and 
156 wt female mice. All mice were 8–12 weeks old. At the end of the fertility 
study the male mice (both Wfs1KO and wt) were used to measure sex hormone 
levels. Eleven adult male Wfs1KO and 12 wt male mice were used for sperm 
morphology and motility study. Three Wfs1KO and 3 wt male mice were used 
to examine testes histology.  
 
 
4.1.2. Growth and development of diabetes  
in Wfs1KO mice (Paper 2) 
In Study 2, we used 21 male Wfs1KO, 21 male wild type (wt), 21 female 
Wfs1KO and 21 female wt mice. At the beginning of the study all mice were 9 
weeks old. The mice were observed until the age of 32 weeks. All mice were 
used in weight analysis and blood glucose measurements. After the longitudinal 
study different hormones (not all in the same mouse) were measured from blood 
of these animals: 20 wt mice and 20 Wfs1KO mice were used for plasma 
insulin measurements, 19 wt and 19 Wfs1KO mice for proinsulin, 10 wt and 10 




4.1.3. Energy metabolism and thyroid function  
in Wfs1KO mice (Paper 3) 
For the measurements of different metabolic parameters 16 male mice 
(8 Wfs1KO and 8 wt) and 16 female mice (8 Wfs1KO, 8wt) at the age of 8–10 
weeks were used. For hormone measurements altogether 52 Wfs1KO mice (20 
for thyroid hormones and 32 for leptin) and 57 wt mice (20 for thyroid 
hormones and 37 for leptin) were used. All mice were 14–20 weeks old. For the 
thyroid histology studies additional 5 Wfs1KO mice (3 males and 2 females) 
and 7 wt mice (4 males and 3 females) at the age of 16–20 weeks were used.  
 
 
4.2. Description of experiments 
4.2.1. Fertility study (Paper 1) 
All male mice, both wt and Wfs1KO, were housed in one cage with two wt 
female mice each. Every morning the females were checked for the presence of 
vaginal plugs, an indication that sexual activity had taken place. If a vaginal 
plug was present, the female was taken away from the cage and placed in 
another one. If there was no vaginal plug after three days, the mice were 
separated and two other females were introduced to the males. This was done 
three times. Thus, at the end of the period, six females had been introduced to 
each male mouse (6 x 13 x 2). Each week, every female was weighed and if 
they had gained weight they were transferred to a single cage, where they 




4.2.2. Blood glucose measurements (Paper 2) 
At the beginning of the study, all mice were 9 weeks old. Until 20 weeks of age, 
non-fasting blood glucose concentration (BGC) from the tail vein was measured 
weekly between 9 a.m. and 11 a.m. using a portative glucometer. After 20 
weeks of age, BGC was measured once every 2 weeks. At 30 weeks of age, an 
intraperitoneal glucose tolerance test (IPGTT) was conducted. After 16 h of 
fasting, animals were weighed and a basal glucose level (Glc 0') was measured 
from the tail vein. The solution of glucose (20 % Glc in 0.9 % NaCl) was 
injected intraperitoneally (2 g of glucose / kg). Blood glucose levels were 
measured 60 and 120 min after the injection (Glc 60’ and Glc 120'). The 
procedure was carried out according to the simplified IPGTT protocol from the 





4.2.3. Longitudinal growth study (Paper 3) 
At the same time as the blood glucose measurements were made, animals were 
weighed using an electronic scale with accuracy of 0.1 g. The following 
characteristics were calculated:  
- The maximal weight gain between the maximal weight during the 
experiment and the weight at 9 weeks of age. 
- The absolute weight gain between the weight at 32 weeks of age and the 
weight at 9 weeks of age and 
- The weight loss between the maximal weight and weight at 32 weeks of age. 
 
 
4.2.4. Study of energy metabolism (Paper 3) 
Mice were at first separated from their littermates and housed in single cage for 
3 weeks. After this adaption period mice were studied alone in a special 
metabolic cage (TSE Systems) for 48 hours. These 48-hour studies were 
repeated three times separated from each other by a one-week break in a single 
cage. All the recordings were done during the last 48-hour period in metabolic 
cage. Mean food and water intake per body weight (g/g and ml/g), mean O2 
consumption (ml/h/kg), CO2 production (ml/h/kg) and heat production 
(kcal/h/kg) were recorded. Movement counts over 48 hours (cnts/48 hrs) of 
each mouse in 3 different directions (X-axis, Y-axis and Z-axis i.e. reared ups) 
were recorded. The mean horizontal (X- and Y-axis) and vertical movements 
(Z-axis) were recorded. 
 
 
4.3. Serum hormone measurements  
Blood samples were taken from mice after they were sacrificed by cervical 
dislocation. Samples were centrifuged for 15–20 minutes at 1000 – 2000xg, 
4°C. Serum or plasma was removed and samples analysed by different ELISA 
kits: USCNLIFE (China) kit for serum testosterone, follicle-stimulating 
hormone (FSH), proinsulin, thyroid stimulating hormone (TSH) and for serum 
thyroxine (T4); Chrystal Chem Inc (USA) for plasma insulin; R&D Systems 
(USA) kit for plasma leptin and Biovendor (Germany) for plasma C-peptide 
measurements. All procedures were preformed according to the user manual of 
every specific kit. The optical density of the wells was determined with the 






4.4. Histological and morphological studies 
4.4.1. Motility and morphology of sperm (Paper 1) 
Sperm were obtained from the cauda epididymides of mature male mice 
previously sacrificed by cervical dislocation. Two hundred spermatozoa per 
male were analyzed, totalling 2200 spermatozoa in the Wfs1KO group and 
2400 in the control group. Sperm motility was observed and recorded by CASA 
(SpermVision™, Minitübe, Germany). The percentage of motile spermatozoa 
and straight-line motile spermatozoa was calculated. Sperm morphology was 
studied on wet preparations made from formal-saline fixed samples, under 
phase-contrast microscope at 1000x magnification. The sperm head 
morphology, sperm tail morphology and the presence of cytoplasmic droplets 
was studied using the methodology described by Kawai et al. (Kawai et al., 
2006). Using sperm head morphology, the percentage of spermatozoa with 
abnormal sperm heads, including triangular, collapsed and hammer heads or 
with a hairpin at the neck, was calculated. Using sperm tail morphology, sperm 
tails were classified into three categories: straight tail, proximal bent tail and 
distal bent tail including angled and hairpin forms. The percentage of every 
form was calculated. The percentage of spermatozoa with none, light-type or 
heavy-type cytoplasmic droplets (CD) was also calculated. 
 
 
4.4.2. Histology of testes (Paper 1) 
The structure of both testes of three wild-type mice and three Wfs1KO mice 
were analyzed (totalling 12 testes). Samples were fixed in 10% buffered 
formalin and embedded in paraffin according to routine methods. Specimens 
were cut at 4μm thickness and stained with hematoxylin and eosin for 
examination by light microscopy. Specific cell counts were performed in each 
testicle in the seminiferous epithelium of five round-shaped seminiferous 
tubules, i.e. cells were counted in 10 tubules per mouse. Two independent, blind 
observers performed the cell counts. 
 
 
4.4.3. Histology of thyroid glands (Paper 3) 
Histology of thyroid gland was studied in 5 Wfs1KO mice (3 males and 2 
females) and 7 wt mice (4 males and 3 females). All mice were 16–20 weeks 
old. Mice were sacrificed and their thyroid glands were separated. Tissue 
samples of thyroid gland were fixed in 10% buffered formalin solution and 
embedded in paraffin with vacuum infiltration processor according to standard 
methods. Specimens were cut at four-µm thickness and stained using the 
hematoxylin-eosin and van Gieson methods for examination by light 
microscopy. The extent of morphological changes in the thyroid glands was 
evaluated by two independent observers in a blinded fashion. 
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4.5. Statistical analysis 
All data was analysed using the statistical software package, SAS version 9.1 
(SAS Institute Inc, Cary, North Carolina, USA) or GraphPad InStat version 
3.0b statistical software package. The Chi-square test or Fisher’s Exact Test 
(when expected values were <5%) was used to compare the fertility rates. The 
2-sample t-test or the Welch ’s t-test was used to analyse the differences in 
various parameters between genotypes and gender. Mean ± SEM are shown.  
P-values < 0.05 were considered statistically significant. 
The standard curve for analysing the ELISA samples was created by a  




5.1. Fertility in male Wfs1KO mice (Paper 1) 
As a result of the fertility study we found out that the pregnancy rate in female 
mice mated with Wfs1KO males tended to be lower than in those mated with wt 
males: 15/78 (19%; 95%CI 11.5–30.0) vs. 25/78 (32%; 95%CI 22.9–43.6), 
p=0.1. We noticed that in the Wfs1KO group there was one male who had pups 
with four out of the six females. This was more than 3 SD above the group’s 
mean. When this male and his six females were excluded from the analysis, the 
pregnancy rate in females mated with Wfs1KO males was significantly lower 
than the pregnancy rate in the control group: 11/72 (15%; 95%CI 7.9–25.7) vs. 
25/78 (32%; 95%CI 21.9–43.6). P < 0.05; (Figure 4). 
 
 
Figure 4. The fertility rate in percentages, with 95% CI in brackets, in 72 female wt 
mice mated with Wfs1KO (n=12) male and in 78 female wt mice mated with wt male 
mice (n=13). 
 
In analysing the fertility of Wfs1KO males, we found that five out of 13 of them 
did not have any litter, whereas all 13 of the control males had at least one litter 
(p < 0.05). There was no significant difference in the litter size: 5.7±0.5 pups in 
the Wfs1KO group vs. 6.6±0.5 pups in the wt group. When analysing the 
occurrence of vaginal plugs we found that out of the six female mice who were 
mated with one male mouse, vaginal plugs occurred in 1.1±0.2 females in the 
Wfs1KO group, compared to their occurrence in 2.5±0.4 females out of six in 
the wt group (p<0.05). 
To find the reason for the altered fertility of male Wfs1KO mice, we 
conducted a study to investigate sperm motility and morphology. Sperm 
motility was not affected in Wfs1KO mice. Surprisingly, the mean percentage 
of motile sperm was even higher in the Wfs1KO mice than in the wt mice, 
whereas no statistical differences were observed in the percentage of straight 
motility (Table 3). The sperm morphology study showed that Wfs1KO males 
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had fewer proximal bent tails than wt males, but had fewer abnormal sperm 
heads than wt males (Table 3, Figure 5). The sperm of Wfs1KO mice also 
tended to have more cytoplasmic droplets, both light-type and heavy-type, but 
the difference was not statistically significant (Table 3, Figure 5). 
 
Table 3. Sperm morphology in male mice according to Kawai et al. (Kawai et al., 
2006). Percentage of spermatozoa (out of 200) having the specific characteristic (mean 
± SEM). CD – cytoplasmic droplets. 
Characteristic Wfs1KO (n=11) WT (n=12) p-value 
Motility  78.0  ± 9.3%  70.0  ± 11.6% 0.04 
Straight motility  66.0  ± 11.7%  58.0 ± 15.4% 0.08 
Sperm without CD  57.0  ± 16.3%  68.9  ± 18.7% 0.07 
Light CD  30.5  ± 10.9%  22.5  ± 13.3% 0.07 
Heavy CD  17.6  ± 6.1%  8.4  ± 6.2% 0.09 
Straight tail  53.1  ± 5.0%  50.2  ± 5.7% 0.1 
Proximal bent tail  14.4  ± 4.1%  21.5  ± 4.4% 0.0003 
Distal bent tail  32.5  ± 7.6%  28.2  ± 5.9% 0.07 
Hairpin at the neck  9.7  ± 2.3%  9.7  ± 2.6% 0.5 
Abnormal head  22.7  ± 5.9%  31.5  ± 12.1% 0.02 
 
 
Figure 5. Four most important abnormalities in sperm morphology: a) light-type 
cytoplasmic droplets; b) heavy-type cytoplasmic droplets; c) proximal bent tails and d) 
abnormal sperm heads. The number of spermatozoa (out of 200) of each mouse having 
the specific characteristic is shown in dots. The mean number of the group is shown 
with a bold line. 
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Testes histology showed the organized architecture of the seminiferous 
epithelium of the seminiferous tubules seen in wt mice was lost in Wfs1KO 
mice (Figure 6).  
 
 
Figure 6. Normal seminiferous epithelium of the seminiferous tubules in a wild-type 
mouse. 
 
Contrary to the wild-type mice, the lumina of the seminiferous tubules in Wfs1-
deficient mice have a typically irregular contour or the lumen may even be 
obliterated. Accumulation of eosinophilic luminal content is seen. Furthermore, 




Figure 7. Altered structure of the seminiferous epithelium in a Wfs1KO mouse. 
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The seminiferous epithelium of Wfs1-deficient mice has reduced numbers of 
Spermatogonia and Sertoli cells, resulting in reduced sperm production 
(Table 4). There were no significant differences between the number and 
structure of Leydig cells between wt and Wfs1KO mice. 
 
Table 4. The number of cells (mean and ± SEM) in the seminiferous epithelium of 
seminiferous tubules in wt and Wfs1KO mice. SG – spermatogonia, PSC – primary 
spermatocytes, SSC – secondary spermatocytes. *p<0.05 
Group SG PSC SSC Spermatids Sperms Sertoli cells 
Control 
(n=3) 
38.12 ± 4.88 54.33 ± 1.46 2.13 ±1.15 134.07 ± 10.63 35.4 ± 9.62 9.17 ± 1.65 
Wfs1 
(n=3) 
23.92 ± 4.91* 47.23 ± 12.07 0 ± 0 109.97 ± 26.42 13.28 ± 6.95* 6.35 ± 0.81* 
 
When measuring the serum concentrations of sex hormones in male Wfs1KO 
mice we found that serum testosterone and FSH concentrations in Wfs1KO 
males (12.0 ± 0.5 nmol/l and 5.6 ± 0.1 mIU/ml respectively) did not differ 




5.2. Growth in Wfs1KO mice (Paper 2) 
At 9 weeks of age, when the experiment started, the male Wfs1KO mice were 
already smaller than the male wt mice (18.69 ± 0.42 g vs. 21.9 ± 0.51 g, 
p < 0.0001); no such difference was observed in females at this point in time. 
The female Wfs1KO mice became statistically lighter than the wt mice from 16 
weeks of age. The average maximum weight and the average maximum weight 
gain over the study period in male Wfs1KO mice were significantly lower than 
in wt males (23.00 ± 0.39 vs. 30.13 ± 0.53 g; p < 0.0001 and 4.36 ± 0.36 vs. 
8.27 ± 0.30 g, p < 0.0001 accordingly). A similar pattern was seen in females: 
the maximum weight and the maximum weight gain over the study period were 
smaller in Wfs1KO mice than in wt females (19.10 ± 0.34 vs. 22.17 ± 0.31 g, 
p < 0.0001 and 2.73 ± 0.19 g vs. 5.39 ± 0.24 g; p < 0.0001 accordingly). 
Wfs1KO mice started to lose weight during the final weeks of the study: the 
average weight loss was 2.02 ± 0.32 g in male Wsf1KO mice and 1.55 ± 0.15 g 
in female Wfs1KO mice. The weight loss between the sexes was not 





Figure 8. The weight curve in male (a) and female (b) Wfs1KO (shown in triangles) 
and wt (shown in squares) mice. The first time-point from the beginning of the study at 
which the difference between the groups became statistically significant (p < 0.05) is 
marked with a *. 
 
 
5.3. Sex differences in the development  
of diabetes in Wfs1KO mice (Paper 2) 
From 24 weeks of age the mean BGC in Wfs1KO males became significantly 
higher than in wt males and continued to rise further. At 32 weeks of age the 
average BGC in male Wfs1KO mice was 9.40 ± 0.60 mmol/l compared to 
7.90 ± 0.20 mmol/ l in wt males (p < 0.05). The opposite effect was seen in 
females: at 32 weeks of age the mean BGC in Wfs1KO mice was lower than in 
wt mice (6.67 ± 0.20 vs. 7.49 ± 0.19 mmol/l, p < 0.05) (Figure 9). The IPGTT 
performed at the age of 30 weeks showed that both male and female Wfs1KO 
mice responded with a significantly higher increase in blood sugar levels than 
wt mice, indicating impaired glucose tolerance or possible diabetes already, 
particularly in males (Table 6). 
 
 
Figure 9. The mean blood glucose concentration in male (a) and female (b) Wfs1KO 
(shown in triangles) and wt (shown in squares) mice. The first time-point from the 
beginning of the study at which the difference between the groups became statistically 













































































Table 6. The results of the IPGTT of WFS1KO and wt mice of both sexes at the age of 
30 weeks.  
Time Wfs1KO male 
mmol/l 




0 min  4.96  ± 0.20  4.53  ±0.19  4.26  ± 0.26  3.72  ± 0.17 
60 min  20.18  ± 0.93a  11.72  ± 0.73  17.06  ± 1.07b  10.49  ± 0.72 
120 min  14.79  ± 0.61a  7.48  ± 0.29  11.0  ± 0.94c  6.82  ± 0.41 
ap<0.0001 vs. wt males; bp<0.0001 vs. wt females; cp<0.05 vs. wt females. 
 
Male Wfs1KO mice had significantly lower plasma insulin levels than wt males 
(57.78 ± 1.80 ng / ml vs. 69.42 ± 3.06 ng / ml; p < 0.01). The mean insulin level 
in male Wfs1KO mice was also significantly lower than in Wfs1KO females 
(70.30 ± 4.42 ng / ml; p < 0.05.) Interestingly, the highest mean plasma 
proinsulin level was seen in the male Wfs1KO group (Table 6), but the 
differences were not statistically significant. However, the Wfs1KO male mice 
had relatively more proinsulin compared to the insulin levels. The proinsulin/ 
insulin ratio in Wfs1KO males (0.09 ± 0.02) was significantly higher than in wt 
males (0.05 ± 0.01; p = 0.05) and in Wfs1KO females (0.04 ± 0.01; p < 0.05). 
The difference in proinsulin/insulin ratio between the females was not 
statistically significant. Plasma C-peptide concentration was measured only in 
male mice; it was significantly reduced in Wfs1KO mice compared to wt mice 
(55.3 ± 14.0 pg / ml vs. 112.7 ± 21.9 pg / ml; p < 0.05). 
 
Table 6. Mean (± SEM) plasma insulin (ng/ ml), proinsulin (ng/ ml) – concentration 
and proinsulin/insulin ratio in different groups. Statistically significant differences 
between the groups are marked with superscript. ap < 0.01 vs. wt males; bp < 0.05 vs. 
female Wfs1KO; cp = 0.05 vs. wt males. 
Hormone Wfs1KO males wt males Wfs1KO females wt females 
Insulin  57.78  ±1.80a, b  69.42  ± 3.06  70.30  ± 4.42  64.36  ± 4.09 
Proinsulin  5.20  ± 1.11  3.37  ± 0.87  2.80  ± 0.73  3.16  ± 0.30 
Proinsulin/insulin  0.09  ± 0.02b,c  0.05  ± 0.01  0.04  ± 0.01  0.05  ± 0.004 
 
 
5.4. Energy metabolism and thyroid function  
in Wfs1KO mice (Paper 3) 
Mean O2 consumption, CO2 or heat production in Wfs1KO mice did not differ 
from those in wt mice. However, there were significant gender differences in 
both genotypes: all three parameters were higher in females. Mean food intake 
per body weight was significantly lower in Wfs1KO males than in wt males 
(0.09 ± 0.01 vs. 0.16 ± 0.02 g/g; p < 0.05). Wfs1KO males were lighter than 
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their wt mates already at the beginning of the experiment and lost much more 
weight during the 48-hour trial in cage than wt males (Table 6). There were no 
differences in horizontal activity between the groups in male mice, but Wfs1KO 
females reared up more frequently (vertical activity) compared to wt female 
mice (199.8 ± 63.5 vs. 39.3± 24.7 cnts/48 hours; p < 0.05) indicating more 
curiosity in this group. Mean characteristics of energy metabolism, food intake 
and physical activity are shown in Table 7. 
 
Table 7. Mean ± SEM values of different parameters measured during the metabolism 
study. Statistically significant differences between the groups are marked with 
superscript. Abbreviations: VO2 – O2 consumption; VCO2 – CO2 production; heat – 
energy produced. ap < 0.05 vs. wt females; bp < 0.05 vs. wt males. cp < 0.05 vs. 









wt males  
(n=8) 
VO2 (ml/h/kg)  3410  ± 127.00
c  3186  ± 61.21b  2806  ± 82.43  2721  ± 117.30 
VCO2 (ml/h/kg)  2925  ± 151.30
c  2850  ± 109.80b 2328  ± 89.49  2376  ± 131.5 
Heat (kcal/h/kg)  16.67  ± 0.66c  15.71  ± 0.35b  13.62  ± 0.41  13.62  ± 0.41 
Weight start (g)  17.21  ± 0.67a  20.28  ± 0.74  20.98  ± 0.51b  23.74  ± 0.96 
Weight end (g)  15.29  ± 1.03a  18.98  ± 1.17  16.69  ± 0.40b  20.19  ± 0.60 
Weight loss (%)  11.80  ± 3.00c  6.84  ± 3.27  20.43  ± 0.41b  16.07  ± 0.86 
Drink per g (ml/g)  0.30  ± 0.04c  0.29  ± 0.05  0.09  ± 0.01  0.09  ± 0.03 
Food per g (g/g)  0.19  ± 0.03c  0.26  ± 0.03  0.09  ± 0.01b  0.16  ± 0.02 
Horizontal activity 
 (cnts/48h) 
 48802  ± 9106 
 
 29576  ± 3360 
 
 34204  ± 6567 
 




 199.8  ± 63.46a  39.26  ± 24.71  86.50  ± 22.73  111.0  ± 36.20 
 
Male Wfs1KO mice had significantly lower levels of plasma leptin than wt 
males (3.37 +/– 0.40 vs 5.82 +/– 0.71 ng/ml; p < 0.01) whereas no such 




Figure 10. The levels of leptin in plasma of Wfs1KO and wt mice (both male and 
female). Lower plasma leptin level in Wfs1KO males compared to wt males is shown 
with a star (p<0.05). 
 
Mean plasma TSH and T4 levels in both sexes did not differ between the 
Wfs1KO and wt groups (Figure 11), but surprisingly, female mice had lower 
mean plasma T4 concentration than the males both in the Wfs1KO group 
(40.8 +/– 4.4 vs. 113.8 +/– 20.5 ng/ml; p < 0.01) as well as in the wt group 
(39.2 +/– 3.5 vs. 131.0 +/– 18.2 ng/ml; p<0.0001; Figure 11).  
 
 
Figure 11. The levels of plasma thyroxine and TSH of Wfs1KO and wt mice (both male 
and female). 
 
We also examined the histological architecture of the thyroid glands. In 
Wfs1KO females the follicles were larger, all filled with colloid. Epithelial cells 
and their nuclei were extremely flat; the mean number of epithelial cells per 
follicle was 10.5 and large amount of interstitium was seen (Figure 12B). In wt 
females very small follicles filled with colloid were dominating, orientation of 
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epithelial cells was irregular, and the mean number of epithelial cells per follicle 
was 10.2 (Figure 12A). 
In Wfs1KO males thyroid follicles were relatively small filled with 
homogeneous colloid; the mean number of epithelial cells per follicle was 13.2. 
Large amount of interstitium was noted (Figure 12D). In comparison in wt 
males there were large spherical follicles filled with colloid. Epithelial cells of 
follicles were regular; the mean number of epithelial cells per follicle was 15.1. 




Figure 12. A) Normal histology of thyroid tissue of female wt mice. H&E, original 
magnification 580x. B) Altered histology of thyroid tissue of female Wfs1KO mice: 
Thyroid follicles with flat epithelial cells are seen. H&E, original magnification 580x. 
C) Normal histology of thyroid tissue of male wt mice. H&E, original magnification 
580x. D) Altered histology of thyroid tissue of male Wfs1KO mice: Thyroid follicles 
with varying size and increased amount of interstitium are seen. H&E, original 
magnification 580x. 
 
Although we could not do the statistical analysis between the groups, the mean 
number of epithelial cells per follicle was higher in males compared to females 




6.1. Fertility of the male Wfs1-deficient mice  
(Paper 1) 
We have shown for the first time that male Wfs1KO mice have reduced fertility 
compared to wt male mice. It is known that primary hypogonadism may occur 
in male patients with WS (Peden et al., 1986; Barrett et al., 1995; Barrett and 
Bundey, 1997; Medlej et al., 2004), but there have been no data about the 
fertility of patients with WS. One reason for this may be the few patients 
available with whom to carry out such a study, or the fact that other clinical 
symptoms, such as diabetes mellitus and vision or hearing impairments, 
dominate and precede the fertility problems.  
Consequently, we investigated whether Wfs1KO male mice have reduced 
fertility and, if so, their possible causes. The pregnancy rate of wt female mice 
was lower when mated with Wfs1KO male mice than when mated with wt 
males. All wt males used in our study gave at least one litter with one female 
out of six, whereas only eight Wfs1KO males out of 13 produced litters, 
indicating impaired fertility in male Wfs1KO mice.  
In order to examine the possible mechanisms causing reduced fertility, we 
examined the sperm of the same males used in the fertility study. Having 
studied the motility and morphology of the sperm in the Wfs1KO and wt 
groups, it was shown that the motility of spermatozoa in Wfs1KO mice was not 
impaired and was even slightly better than in the wt animals; however, many 
changes in sperm morphology were found. The most statistically significant 
difference was that the sperm of Wfs1KO mice contained fewer spermatozoa 
with proximal bent tails than the sperm of wt mice. The in vitro fertilisation rate 
in mice has been shown to be positively correlated to proximal bent tails, but 
negatively to heavy-type CD and distal bent tails. These last two characteristics 
were higher in Wfs1KO mice compared to wt mice, but the difference did not 
reach statistical significance (p < 0.09 and 0.07, respectively). We did find that 
Wfs1KO males had fewer abnormal sperm heads; however, the impact of an 
abnormal sperm head on fertility has been found to be much smaller than the 
impact of differently bent tails or cytoplasmic droplets, as seen in the study by 
Kawai et al. where a high percentage of abnormal sperm heads was associated 
with a relatively good fertilisation rate (Kawai et al., 2006).  
Testicular histology showed a normal pattern of seminiferous epithelium in 
the tubules of wt mice, which was lost in Wfs1KO mice. Several segments of 
seminiferous tubules in Wfs1KO mice had no spermatogenic cells at all. The 
number of spermatogonia and Sertoli cells essential for effective 
spermatogenesis was decreased, leading to reduced sperm production. Thus, 
both sperm morphology and quantity is affected in Wfs1KO mice; however, the 
number and structure of Leydig cells responsible for testosterone synthesis did 
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not different between the Wfs1KO and wt mice. Normal testosterone levels in 
the two groups also confirmed this.  
The mechanism by which wolframin deficiency may cause impaired fertility 
and changes in sperm morphology and quantity is not clear. One possible 
explanation may be through increased endoplasmic reticulum (ER) stress, 
which has been shown to cause progressive cell loss in pancreatic β-cells in 
Wfs1-deficient mice (Ishihara et al., 2004; Ueda et al., 2005; Yamada et al., 
2006). ER stress enhances Wfs1 gene expression and Wfs1-deficient mice are 
more susceptible to ER stress-induced apoptosis than wild-type mice (Ishihara 
et al., 2004).  
Wfs1 is also expressed in the testes of mice (Kõks S, 2008), so it is possible 
that increased ER stress in the testes of Wfs1KO mice may cause changes in 
spermatogenesis. Further studies, including electron microscopic studies of the 
endoplasmic reticulum of spermatozoa and the epithelium of seminiferous 
tubules in Wfs1KO mice, are necessary to confirm or reject our hypothesis. 
Another possible reason for impaired fertility in Wfs1KO mice may be due 
to changes in the hypothalamic-pituitary axis. It is known that patients with WS 
have disturbed anterior pituitary function (Medlej et al., 2004), and we 
ourselves have been shown changes in the gene expression levels of GH, 
POMC, and NPY in different parts of the brain (Koks et al., 2009). Therefore, 
we also measured serum FSH and testosterone levels in these mice. We chose 
these two hormones because they both play an important role in 
spermatogenesis; however, we did not find any differences in their levels. 
Unfortunately, we did not have enough serum to measure LH, but it is unlikely 
that serum LH concentrations would have been different due to comparable 
serum testosterone concentrations as well as the number and structure of Leydig 
cells. This observation suggests that it is unlikely that altered gonadotrophin 
levels would cause the impaired fertility in these mice. As the number of Sertoli 
cells was significantly lower in the Wfs1KO group, inhibin B should be 
measured in further studies.  
We cannot exclude the possibility that part of the impaired fertility in 
Wfs1KO male mice may be explained by different sexual behaviours. It is 
known that patients with WS frequently have psychiatric problems (Swift et al., 
1990) and therefore may have defects in sexual behaviour. The occurrence of 
vaginal plugs in female mice was significantly lower when mated with Wfs1KO 
males, in comparison to wt males. However, the occurrence of vaginal plugs is 
not a very reliable method, since the plug lasts only couple of hours and can 
easily be missed. Specially designed studies with video recording are necessary 





6.2. Growth retardation (Paper 2) 
We studied weight in Wfs1KO mice longitudinally from the age of 9 weeks 
until the age of 32 weeks. Over the last weeks of this study period, both female 
and male Wfs1KO mice significantly lost weight (8.4% and 8.7%, 
respectively). These types of longitudinal studies have also been carried out 
before (Ishihara et al., 2004; Riggs et al., 2005); however, in previous studies 
mice did not present with such severe weight loss. In one study, male knock-out 
mice grew similar to the wild-type mice until the age of 24 weeks (Riggs et al., 
2005), whereas in our case male Wfs1KO mice were statistically smaller 
already at the beginning of the study. The present study used only mice with the 
isogenic 129S6 background and the study lasted until 32 weeks of age. Thus, 
these differences in genomic background and shorter duration of the experiment 
may explain the differences in the weight pattern in mice between our study and 
the study by Ishihara et al. (Ishihara et al., 2004) and Riggs et al. (Riggs et al., 
2005).    
6.3. Sex related differences in developing  
of diabetes in Wfs1KO mice (Paper 2) 
This is the first study to describe detailed sex-related longitudinal changes in 
BGC in Wfs1KO mice – an animal model for WS. Changes in blood glucose 
levels were studied from 9 weeks of age, at which time mice are considered 
young adults. Over the next 21 weeks, both male and female Wfs1KO mice 
developed impaired glucose tolerance according to the IPGTT results at 30 
weeks of age. As there are no specific criteria for diabetes in mice, the results of 
IPGTT could already suggest possible overt diabetes, particularly in males, as 
significant hyperglycaemia with accompanied weight loss was seen only in 
male Wfs1KO mice. Their genetic background can explain the relatively mild 
phenotype of diabetes in these mice. Ishihara et al. (Ishihara et al., 2004) 
showed that the development and severity of diabetes in Wfs1KO mice depends 
on the mouse’s genetic background: in the F2 generation of B6 and 129 hybrids, 
60% of mice developed overt diabetes at 36 weeks of age. Further back-
crossing to B6 weakened diabetic phenotype in these mice, although that study 
only used male mice, as females had previously shown to have a milder 
phenotype (Ishihara et al., 2004). Riggs et al. (Riggs et al., 2005) also used only 
male mice to study the blood glucose levels in Wfs1KO mice. They used a 
mouse model with conditional deletion of Wfs1 in beta-cells. These knock-out 
males had significantly higher BGCs starting from the 24th week of age, similar 
to our study. The present study used only mice with the isogenic 129S6 
background and the study lasted until 32 weeks of age. Thus, these differences 
in genomic background and shorter duration of the experiment may explain the 
differences in the phenotype of diabetes in male mice between our study and the 
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study by Ishihara et al. (Ishihara et al., 2004) and Riggs et al. (Riggs et al., 
2005). 
In the present study, only male Wfs1KO mice developed the non-fasting 
hyperglycaemia at 24 weeks of age. In classical rodent models of beta-cell 
failure, oestrogens at physiological concentrations protect pancreatic beta-cells 
against lipotoxicity (Pick et al., 1998), oxidative stress (Contreras et al., 2002; 
Eckhoff et al., 2003; Eckhoff et al., 2004; Le May et al., 2006), and apoptosis 
(Pick et al., 1998; Contreras et al., 2002), while 17-β–estradiol administration to 
rodents produces islet hypertrophy (Zhu et al., 1998), increases pancreas insulin 
concentration, and enhances insulin secretion (Alonso-Magdalena et al., 2008). 
The prevalence of diabetes, especially diabetic syndromes with insulin 
deficiency, is lower in premenopausal women, suggesting that the female 
hormone 17-β-estradiol protects pancreatic beta-cell function (Liu and Mauvais-
Jarvis, 2010).  
Some data indicate that the onset of diabetes in humans with WS tends to 
start earlier in boys than in girls (Hardy et al., 1999; Smith et al., 2004), which 
suggests that the sex difference in the development of diabetes also exists in 
humans with WS.  
In Wfs1-deficient mice, the development of diabetes has been associated 
with increased endoplasmic reticulum stress and apoptosis in pancreatic beta-
cells, leading to insufficient insulin secretion (Ishihara et al., 2004). Thus, the 
oestrogen receptors present in beta-cells can enhance islet survival (Liu et al., 
2009). They also improve islet lipid homeostasis (Louet et al., 2004) and insulin 
biosynthesis (Alonso-Magdalena et al., 2008).  
The data about gender differences related to diabetes in humans are 
conflicting. Some human data indicate that females are intrinsically more 
insulin-resistant than males, possibly because of specific sex-linked gene 
expression and the resulting differences in metabolic control (Mittendorfer, 
2005). On the other hand, despite having lower fat mass, the prevalence of 
diabetes and early abnormalities of glucose metabolism is higher in men than in 
women (Kuhl et al., 2005; Macotela et al., 2009).  
In different animal models of glucose intolerance, insulin resistance, and 
diabetes, male mice usually show a stronger phenotype than females (Clark et 
al., 1983; Zierath et al., 1997; Li et al., 2000; Macotela et al., 2009). The mean 
plasma insulin level in our male Wfs1KO mice was significantly lower than in 
wt mice, similar to the study by Ishihara et al. (Ishihara et al., 2004) and Riggs 
et al. (Riggs et al., 2005). Unfortunately, their studies did not include female 
mice. 
We also measured plasma proinsulin level in these mice and found that the 
mean proinsulin level tended to be higher in male Wfs1KO mice than wt mice. 
The increased proinsulin/insulin ratio in male mutant mice indicates that there 
may be problems converting proinsulin to insulin. This was later confirmed by 
Hatanaka et al. (2011), who found that Wfs1-null islets have impaired 
proinsulin processing, resulting in an increased circulating proinsulin level 
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(Hatanaka et al., 2011). There are data indicating that prohormone convertase 2 
(PC2) is absent in some WS patients (Gabreels et al., 1998), which means that 
disturbances converting prohormones into biologically active forms (such as 
proinsulin to insulin) may exist. The other reason may be impaired acidification 
of insulin granules required before their exocytosis from β-cells (Hatanaka et 
al., 2011). As the clinical picture and changes in BGC were more pronounced in 
males, their plasma C-peptide levels were also measured. These measurements 
found decreased C-peptide levels in male mutant mice, which suggests that in 
WS there may be also a defect in insulin processing that through increased 
endoplasmic reticulum stress and apoptosis in pancreatic beta-cells in the long-
term leads to insulin deficiency. This process is probably much less rapid than 
the autoimmune pancreatic beta-cell destruction seen in type 1 diabetes; 
however, the fact that C-peptide was only measured in males means it is not 
possible to reach any conclusions regarding the sex differences in plasma  
C-peptide concentrations.  
The study showed an interesting sex-related phenotype of diabetes in 
Wfs1KO mice. Male Wfs1KO mice developed overt diabetes with decreased 
plasma insulin levels – a phenotype seen more in Type 1 diabetes – whereas 
female knock-out mice developed impaired glucose tolerance with relatively 
high insulin levels – a phenotype more similar to Type 2 diabetes. The 
relatively high insulin level in Wfs1KO females may also explain their 
relatively low BGC. Recently, variants in the Wfs1 gene have been shown to be 
associated with Type 2 diabetes (Sandhu et al., 2007; Franks et al., 2008; 
Sparso et al., 2008). Some medications used for treating Type 2 diabetes have 
also been found to be effective in preventing pancreatic beta-cell apoptosis in 
Wfs1KO mice (Akiyama et al., 2009). 
 
 
6.4. Energy metabolism and  
thyroid function (Paper 3) 
This is the first study to describe the energy metabolism and thyroid function in 
Wfs1KO mice – an animal model for WS.  
Patients with neurodegenerative disorders such as Alzheimer’s, Parkinson’s, 
or Huntington’s disease have impaired glucose metabolism, increased insulin 
resistance, and abnormal appetite regulation (Cai et al., 2012). Patients with 
Huntington’s disease show severe weight loss in spite of having high caloric 
intake (Morales et al., 1989; Trejo et al., 2004; Cai et al., 2012), and they also 
have higher energy expenditure compared to controls (Pratley et al., 2000; Stoy 
and McKay, 2000; Gaba et al., 2005; Cai et al., 2012). The same has been 
shown in patients with Parkinson’s disease (Cai et al., 2012). Abnormally low 
leptin levels have been shown in patients with Alzheimer’s disease (Olsson et 
al., 1998; Power et al., 2001). Increasing evidence suggests that there is a link 
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in Huntingdon's and Parkinson’s disease between the progression of the disease 
and metabolic dysfunction (Cai et al., 2012).  
Several recent studies have demonstrated that therapies targeted to restore 
metabolic homeostasis may also improve cognitive and motor function, as well 
as increase lifespan in patients with Alzheimer’s or Huntington’s disease 
(Watson et al., 2005; Martin et al., 2009). Therefore, it is also very important to 
know the metabolism in Wolfram syndrome, another neurodegenerative 
disorder.  
In this study, we focused on energy metabolism and thyroid function; 
however, we did not find such a difference in the energy metabolism of 
Wfs1KO mice compared to wt mice.  
We analysed our mice for 48 hours in metabolic cages where O2 
consumption and CO2 and energy production were measured, while vertical and 
horizontal motor activity and food and water consumption were registered. 
These cages have been used successfully in many animal studies to describe the 
energy metabolism in mice (Mauer et al., 2010; Jung et al., 2013).  
In our study, Wfs1KO mice were smaller than wt mice. Wfs1KO mice also 
lost more weight than the wt mice during the 48-hour period, possibly due to 
lower food intake. Male Wfs1KO mice ate less than wt mice, which may be due 
to the emotional stress caused by an unfamiliar environment. Female mice 
showed their insecurity in the unusual environment by rearing up more often 
than their wt littermates. Impaired behavioural adaption to stress in Wfs1KO 
mice has been shown before (Luuk et al., 2009), and it is therefore the likely 
mechanism for that increased weight loss. The same study also showed that the 
exposure to stress in female Wfs1KO mice induced a remarkable elevation of 
plasma corticosterone level compared to the wt littermates (Luuk et al., 2009).  
The other possible explanation as to why we could not see the differences in 
energy metabolism (We expected to see a hypermetabolic state similar to 
Huntington’s (Aziz et al., 2008; Goodman et al., 2008) or Parkinson’s disease 
(Levi et al., 1990; Markus et al., 1992)) in Wfs1KO mice is the age of our 
animals; namely, our animals were relatively young: 11–13 weeks in the 
metabolic cage study and 14–20 weeks at the time of blood sampling for 
hormone measurements and thyroid tissue removal for the histology study. 
However, as we have shown, overt diabetes was not yet present at this age in 
these mice (Noormets et al., 2011), though it is the diabetes that develops first 
in patients with WS out of many clinical problems they have (de Heredia et al., 
2013). Thus, it is likely that if we had used older mice, the likelihood of 
discovering disturbances in energy metabolism would have been higher. 
As expected, mean plasma leptin level in male Wfs1KO mice was 
significantly lower than in wt mice, as they probably also had lower fat mass – 
an important determinant of leptin level. This, however, is purely speculation, 
as we did not measure the length in these mice to calculate their BMI – a 
marker of body fat mass. In patients with Huntington’s disease, another 
neurodegenerative disease, low leptin levels have been found, suggesting 
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negative energy balance (Popovic et al., 2004). On the other hand, female 
Wfs1KO mice also had lower body weight than wild-type females, but they did 
not show such a decline in serum leptin levels suggesting some degree of leptin 
resistance. This resistance to leptin, a strong anorexigenic peptide, did not allow 
suppression of appetite, and the female knock-out mice ate more and in this way 
lost less weight than male Ws1KO animals in spite of their increased O2 
consumption. No such resistance to leptin was seen in male Wfs1KO animals.  
Sex-related differences seem to be common in Wfs1KO mice. We have 
shown that only the male Wfs1KO mice had impaired fertility, and only the 
male mice developed overt diabetes, whereas female Wfs1KO mice presented 
even very low glucose levels during fasting, followed by significant increase of 
blood sugar levels in IPGTT (Noormets et al., 2011). We also found a sex-
related difference in thyroid function in this study. It seems that males are more 
affected by the deletion of the Wfs1 gene than females. There are also data from 
humans showing that the onset of diabetes, the first manifestation of WS, is 
earlier in boys than in girls (Barrett and Bundey, 1997; Hardy et al., 1999; 
Smith et al., 2004).  
As Wfs1 is expressed in thyroid tissue both in mice and in humans (Kõks S, 
2008; De Falco et al., 2012), we also investigated thyroid function and 
morphology. We did not find that Wfs1 deficiency had any effect on thyroid 
function in these mice; however, to our great surprise, we found significantly 
lower plasma thyroxine levels in females in both groups compared to the male 
animals. McLachlan et al. have described the level of thyroxine as differing 
greatly between the mouse strains (McLachlan et al., 2011), but in our case all 
mice studied were of the same background, and therefore the sex difference in 
thyroid function could not be explained by this factor. A gender difference in 
thyroxine levels has been noticed before: according to the Mouse Phenome 
Database (http://phenome.jax.org), thyroxine levels differ between the sexes 
greatly, depending on the background of different mice. Pohlenz et al. (Pohlenz 
et al., 1999) also showed similar sex-related differences in TSH levels within 
one mouse strain. It is probably for these reasons that frequently only female 
mice are used to describe thyroid function in mice.  
The histology of thyroid tissue also showed some differences between sexes, 
with a higher mean number of epithelial cells per follicle in male compared to 
female mice and more flattened epithelial cells in Wfs1KO females. A lower 
number of epithelial cells could lead to decreased thyroid function characterised 
by low thyroxine level, a picture seen in our female mice.  
Further studies are necessary to clarify the precise clinical significance of 








1. The fertility of Wfs1KO male mice is impaired compared to wt male mice. 
The reason for this is the changes in sperm morphology and in the 
morphology of the testes. Sperm motility was not affected in Wfs1KO mice.  
2. Wfs1KO males have fewer proximal bent tails and fewer abnormal sperm 
heads than wt males, and both findings tend to be associated with lower in 
vitro fertilisation rates. Testicular histology showed a loss of normal 
seminiferous epithelium in the tubules of Wfs1KO mice and decreased 
number of spermatogonia and Sertoli cells, leading to reduced sperm 
production.  
3. There are severe sex-related differences in the development of growth failure 
and diabetes. Growth failure in male Wfs1KO mice is already present from 
birth, whereas in females it develops during the first months of life. Severe 
glucose intolerance developed in both sexes, but overt diabetes with low 
plasma insulin levels occurs only in male Wfs1KO mice, whereas female 
Wfs1KO mice are even hypoglycaemic with relatively high insulin levels.  
4. For the first time, we showed that one of the reasons for developing WS 
related diabetes is not the insulin deficiency itself, but the impairment in 
converting proinsulin to active insulin. A proof for that is the increased 
proinsulin/insulin ratio in male Wfs1 mice, confirmed later by other 
investigators. 
5. The energy metabolism did not differ significantly between Wfs1 KO and wt 
mice; however, we found that female mice had lower mean plasma T4 
concentration than the males, both in the Wfs1KO as well as in the wt group. 
Our data also suggest some degree of leptin resistance in female Wfs1KO 






Akiyama M, Hatanaka M, Ohta Y, Ueda K, Yanai A, Uehara Y, Tanabe K, Tsuru M, 
Miyazaki M, Saeki S, Saito T, Shinoda K, Oka Y, Tanizawa Y. 2009. Increased 
insulin demand promotes while pioglitazone prevents pancreatic beta cell apoptosis 
in Wfs1 knockout mice. Diabetologia 52(4):653–663. 
al-Sheyyab M, Jarrah N, Younis E, Shennak MM, Hadidi A, Awidi A, el-Shanti H, 
Ajlouni K. 2001. Bleeding tendency in Wolfram syndrome: a newly identified 
feature with phenotype genotype correlation. European journal of pediatrics 
160(4):243–246. 
Alemzadeh R WD. 2007. Diabetes mellitus in children. In: Kliegman RM BR, Jenson 
AB, Stanton BF, ed. Nelson Textbook of Pediatrics. 18th Edition ed. Philadelphia: 
Elsvier. p 2404–2427. 
Alonso-Magdalena P, Ropero AB, Carrera MP, Cederroth CR, Baquie M, Gauthier BR, 
Nef S, Stefani E, Nadal A. 2008. Pancreatic insulin content regulation by the 
estrogen receptor ER alpha. PloS one 3(4):e2069. 
Amr S, Heisey C, Zhang M, Xia XJ, Shows KH, Ajlouni K, Pandya A, Satin LS, El-
Shanti H, Shiang R. 2007. A homozygous mutation in a novel zinc-finger protein, 
ERIS, is responsible for Wolfram syndrome 2. American journal of human genetics 
81(4):673–683. 
Aziz NA, van der Marck MA, Pijl H, Olde Rikkert MG, Bloem BR, Roos RA. 2008. 
Weight loss in neurodegenerative disorders. Journal of neurology 255(12):1872–
1880. 
Awata T, Inoue K, Kurihara S, Ohkubo T, Inoue I, Abe T, Takino H, Kanazawa Y, 
Katayama S. 2000. Missense variations of the gene responsible for Wolfram 
syndrome (WFS1/wolframin) in Japanese: possible contribution of the Arg456His 
mutation to type 1 diabetes as a nonautoimmune genetic basis. Biochemical and 
biophysical research communications 268(2):612–616. 
Barrett TG. 2001. Mitochondrial diabetes, DIDMOAD and other inherited diabetes 
syndromes. Best practice & research Clinical endocrinology & metabolism 
15(3):325–343. 
Barrett TG, Bundey SE. 1997. Wolfram (DIDMOAD) syndrome. Journal of medical 
genetics 34(10):838–841. 
Barrett TG, Bundey SE, Fielder AR, Good PA. 1997. Optic atrophy in Wolfram 
(DIDMOAD) syndrome. Eye 11 ( Pt 6):882–888. 
Barrett TG, Bundey SE, Macleod AF. 1995. Neurodegeneration and diabetes: UK 
nationwide study of Wolfram (DIDMOAD) syndrome. Lancet 346(8988):1458–
1463. 
Barrientos A, Volpini V, Casademont J, Genis D, Manzanares JM, Ferrer I, Corral J, 
Cardellach F, Urbano-Marquez A, Estivill X, Nunes V. 1996. A nuclear defect in 
the 4p16 region predisposes to multiple mitochondrial DNA deletions in families 
with Wolfram syndrome. The Journal of clinical investigation 97(7):1570–1576. 
Baz P, Azar ST, Medlej R, Bejjani R, Halabi G, Salti I. 1999. Role of early fundoscopy 
for diagnosis of Wolfram syndrome in type 1 diabetic patients. Diabetes care 
22(8):1376–1378. 
Bespalova IN, Van Camp G, Bom SJ, Brown DJ, Cryns K, DeWan AT, Erson AE, 
Flothmann K, Kunst HP, Kurnool P, Sivakumaran TA, Cremers CW, Leal SM, 
Burmeister M, Lesperance MM. 2001. Mutations in the Wolfram syndrome 1 gene 
14
54 
(WFS1) are a common cause of low frequency sensorineural hearing loss. Human 
molecular genetics 10(22):2501–2508. 
Boutzios G, Livadas S, Marinakis E, Opie N, Economou F, Diamanti-Kandarakis E. 
2011. Endocrine and metabolic aspects of the Wolfram syndrome. Endocrine 
40(1):10–13. 
Bundey S, Poulton K, Whitwell H, Curtis E, Brown IA, Fielder AR. 1992. 
Mitochondrial abnormalities in the DIDMOAD syndrome. Journal of inherited 
metabolic disease 15(3):315–319. 
Cai H, Cong WN, Ji S, Rothman S, Maudsley S, Martin B. 2012. Metabolic dysfunction 
in Alzheimer's disease and related neurodegenerative disorders. Current Alzheimer 
research 9(1):5–17. 
Cano A, Molines L, Valero R, Simonin G, Paquis-Flucklinger V, Vialettes B, French 
Group of Wolfram S. 2007a. Microvascular diabetes complications in Wolfram 
syndrome (diabetes insipidus, diabetes mellitus, optic atrophy, and deafness 
[DIDMOAD]): an age- and duration-matched comparison with common type 1 
diabetes. Diabetes care 30(9):2327–2330. 
Cano A, Rouzier C, Monnot S, Chabrol B, Conrath J, Lecomte P, Delobel B, Boileau P, 
Valero R, Procaccio V, Paquis-Flucklinger V, French Group of Wolfram S, 
Vialettes B. 2007b. Identification of novel mutations in WFS1 and genotype-
phenotype correlation in Wolfram syndrome. American journal of medical genetics 
Part A 143A(14):1605–1612. 
Chaussenot A, Bannwarth S, Rouzier C, Vialettes B, Mkadem SA, Chabrol B, Cano A, 
Labauge P, Paquis-Flucklinger V. 2011. Neurologic features and genotype-pheno-
type correlation in Wolfram syndrome. Annals of neurology 69(3):501–508. 
Chen YF, Wu CY, Kirby R, Kao CH, Tsai TF. 2010. A role for the CISD2 gene in 
lifespan control and human disease. Annals of the New York Academy of Sciences 
1201:58–64. 
Cheng S, Wu Y, Wu W, Zhang D. 2013. Association of rs734312 and rs10010131 
polymorphisms in WFS1 gene with type 2 diabetes mellitus: a meta-analysis. 
Endocrine journal 60(4):441–447. 
Clark JB, Palmer CJ, Shaw WN. 1983. The diabetic Zucker fatty rat. Proceedings of the 
Society for Experimental Biology and Medicine Society for Experimental Biology 
and Medicine 173(1):68–75. 
Collier D. 2008. Wolframin: pathology and function. In: Kõks S VE, ed. Wfs1 protein 
(wolframin): emerging link between the emotional brain and 
endocrine pancreas: Kerala: Research Signpost. 
Collier DA, Barrett TG, Curtis D, Macleod A, Arranz MJ, Maassen JA, Bundey S. 
1996. Linkage of Wolfram syndrome to chromosome 4p16.1 and evidence for 
heterogeneity. American journal of human genetics 59(4):855–863. 
Contreras JL, Smyth CA, Bilbao G, Young CJ, Thompson JA, Eckhoff DE. 2002. 
17beta-Estradiol protects isolated human pancreatic islets against proinflammatory 
cytokine-induced cell death: molecular mechanisms and islet functionality. 
Transplantation 74(9):1252–1259. 
Cremers CW, Wijdeveld PG, Pinckers AJ. 1977. Juvenile diabetes mellitus, optic 
atrophy, hearing loss, diabetes insipidus, atonia of the urinary tract and bladder, and 
other abnormalities (Wolfram syndrome). A review of 88 cases from the literature 
with personal observations on 3 new patients. Acta paediatrica Scandinavica 
Supplement(264):1–16. 
55 
Cryns K, Thys S, Van Laer L, Oka Y, Pfister M, Van Nassauw L, Smith RJ, 
Timmermans JP, Van Camp G. 2003. The WFS1 gene, responsible for low 
frequency sensorineural hearing loss and Wolfram syndrome, is expressed in a 
variety of inner ear cells. Histochemistry and cell biology 119(3):247–256. 
Davidson IR, McNicholl JM, O'Donnell J. 1993. Successful pregnancy in two sisters 
with Wolfram syndrome. Irish medical journal 86(1):33–34. 
De Falco M, Manente L, Lucariello A, Baldi G, Fiore P, Laforgia V, Baldi A, 
Iannaccone A, De Luca A. 2012. Localization and distribution of wolframin in 
human tissues. Frontiers in bioscience 4:1986–1998. 
de Heredia ML, Cleries R, Nunes V. 2013. Genotypic classification of patients with 
Wolfram syndrome: insights into the natural history of the disease and correlation 
with phenotype. Genetics in medicine: official journal of the American College of 
Medical Genetics 15(7):497–506. 
Dhalla MS, Desai UR, Zuckerbrod DS. 2006. Pigmentary maculopathy in a patient with 
Wolfram syndrome. Canadian journal of ophthalmology Journal canadien 
d’ophtalmologie 41(1):38–40. 
Domenech E, Gomez-Zaera M, Nunes V. 2006. Wolfram/DIDMOAD syndrome, a 
heterogenic and molecularly complex neurodegenerative disease. Pediatric 
endocrinology reviews : PER 3(3):249–257. 
Eckhoff DE, Eckstein C, Smyth CA, Vilatoba M, Bilbao G, Rahemtulla FG, Young CJ, 
Anthony Thompson J, Chaudry IH, Contreras JL. 2004. Enhanced isolated 
pancreatic islet recovery and functionality in rats by 17beta-estradiol treatment of 
brain death donors. Surgery 136(2):336–345. 
Eckhoff DE, Smyth CA, Eckstein C, Bilbao G, Young CJ, Thompson JA, Contreras JL. 
2003. Suppression of the c-Jun N-terminal kinase pathway by 17beta-estradiol can 
preserve human islet functional mass from proinflammatory cytokine-induced 
destruction. Surgery 134(2):169–179. 
El-Shanti H, Lidral AC, Jarrah N, Druhan L, Ajlouni K. 2000. Homozygosity mapping 
identifies an additional locus for Wolfram syndrome on chromosome 4q. American 
journal of human genetics 66(4):1229–1236. 
Farmer A, Ayme S, de Heredia ML, Maffei P, McCafferty S, Mlynarski W, Nunes V, 
Parkinson K, Paquis-Flucklinger V, Rohayem J, Sinnott R, Tillmann V, Tranebjaerg 
L, Barrett TG. 2013. EURO-WABB: an EU rare diseases registry for Wolfram 
syndrome, Alstrom syndrome and Bardet-Biedl syndrome. BMC pediatrics 13:130. 
Fishman L, Ehrlich RM. 1986. Wolfram syndrome: report of four new cases and a 
review of literature. Diabetes care 9(4): 405–408. 
Fonseca SG, Fukuma M, Lipson KL, Nguyen LX, Allen JR, Oka Y, Urano F. 2005. 
WFS1 is a novel component of the unfolded protein response and maintains 
homeostasis of the endoplasmic reticulum in pancreatic beta-cells. The Journal of 
biological chemistry 280(47):39609–39615. 
Franks PW, Rolandsson O, Debenham SL, Fawcett KA, Payne F, Dina C, Froguel P, 
Mohlke KL, Willer C, Olsson T, Wareham NJ, Hallmans G, Barroso I, Sandhu MS. 
2008. Replication of the association between variants in WFS1 and risk of type 2 
diabetes in European populations. Diabetologia 51(3):458–463. 
Fraser FC, Gunn T. 1977. Diabetes mellitus, diabetes insipidus, and optic atrophy. An 
autosomal recessive syndrome? Journal of medical genetics 14(3):190–193. 
Fukuoka H, Kanda Y, Ohta S, Usami S. 2007. Mutations in the WFS1 gene are a 
frequent cause of autosomal dominant nonsyndromic low-frequency hearing loss in 
Japanese. Journal of human genetics 52(6):510–515. 
56 
Gaba AM, Zhang K, Marder K, Moskowitz CB, Werner P, Boozer CN. 2005. Energy 
balance in early-stage Huntington disease. The American journal of clinical nutrition 
81(6):1335–1341. 
Gabreels BA, Swaab DF, de Kleijn DP, Dean A, Seidah NG, Van de Loo JW, Van de 
Ven WJ, Martens GJ, Van Leeuwen FW. 1998. The vasopressin precursor is not 
processed in the hypothalamus of Wolfram syndrome patients with diabetes 
insipidus: evidence for the involvement of PC2 and 7B2. The Journal of clinical 
endocrinology and metabolism 83(11):4026–4033. 
Galluzzi P, Filosomi G, Vallone IM, Bardelli AM, Venturi C. 1999. MRI of Wolfram 
syndrome (DIDMOAD). Neuroradiology 41(10):729–731. 
Ganie MA, Bhat D. 2009. Current developments in Wolfram syndrome. Journal of 
pediatric endocrinology & metabolism : JPEM 22(1):3–10. 
Ganie MA, Laway BA, Nisar S, Wani MM, Khurana ML, Ahmad F, Ahmed S, Gupta 
P, Ali I, Shabir I, Shadan A, Ahmed A, Tufail S. 2011. Presentation and clinical 
course of Wolfram (DIDMOAD) syndrome from North India. Diabetic medicine : a 
journal of the British Diabetic Association 28(11):1337–1342. 
Gharanei S, Zatyka M, Astuti D, Fenton J, Sik A, Nagy Z, Barrett TG. 2013. Vacuolar-
type H+–ATPase V1A subunit is a molecular partner of Wolfram syndrome 1 
(WFS1) protein, which regulates its expression and stability. Human molecular 
genetics 22(2):203–217. 
Glastras SJ, Craig ME, Verge CF, Chan AK, Cusumano JM, Donaghue KC. 2005. The 
role of autoimmunity at diagnosis of type 1 diabetes in the development of thyroid 
and celiac disease and microvascular complications. Diabetes care 28(9):2170–
2175. 
Goodman AO, Murgatroyd PR, Medina-Gomez G, Wood NI, Finer N, Vidal-Puig AJ, 
Morton AJ, Barker RA. 2008. The metabolic profile of early Huntington's disease – 
a combined human and transgenic mouse study. Experimental neurology 
210(2):691–698. 
Guo X, Shen S, Song S, He S, Cui Y, Xing G, Wang J, Yin Y, Fan L, He F, Zhang L. 
2011. The E3 ligase Smurf1 regulates Wolfram syndrome protein stability at the 
endoplasmic reticulum. The Journal of biological chemistry 286(20):18037–18047. 
Haghighi A, Haghighi A, Setoodeh A, Saleh-Gohari N, Astuti D, Barrett TG. 2013. 
Identification of homozygous WFS1 mutations (p.Asp211Asn, p.Gln486*) causing 
severe Wolfram syndrome and first report of male fertility. European journal of 
human genetics : EJHG 21(3):347–351. 
Hansen L, Eiberg H, Barrett T, Bek T, Kjaersgaard P, Tranebjaerg L, Rosenberg T. 
2005. Mutation analysis of the WFS1 gene in seven Danish Wolfram syndrome 
families; four new mutations identified. European journal of human genetics : EJHG 
13(12):1275–1284. 
Hardy C, Khanim F, Torres R, Scott-Brown M, Seller A, Poulton J, Collier D, Kirk J, 
Polymeropoulos M, Latif F, Barrett T. 1999. Clinical and molecular genetic analysis 
of 19 Wolfram syndrome kindreds demonstrating a wide spectrum of mutations in 
WFS1. American journal of human genetics 65(5):1279–1290. 
Hatanaka M, Tanabe K, Yanai A, Ohta Y, Kondo M, Akiyama M, Shinoda K, Oka Y, 
Tanizawa Y. 2011. Wolfram syndrome 1 gene (WFS1) product localizes to 
secretory granules and determines granule acidification in pancreatic beta-cells. 
Human molecular genetics 20(7):1274–1284. 
57 
Hershey T, Lugar HM, Shimony JS, Rutlin J, Koller JM, Perantie DC, Paciorkowski 
AR, Eisenstein SA, Permutt MA, Washington University Wolfram Study G. 2012. 
Early brain vulnerability in Wolfram syndrome. PloS one 7(7):e40604. 
Hildebrand MS, Sorensen JL, Jensen M, Kimberling WJ, Smith RJ. 2008. Autoimmune 
disease in a DFNA6/14/38 family carrying a novel missense mutation in WFS1. 
American journal of medical genetics Part A 146A(17):2258–2265. 
Hofmann M, Boehmer H, Zumbach M, Borcea V, Grauer A, Kasperk C, Heilmann P, 
Ziegler R, Wahl P, Nawroth PP. 1997a. [The Wolfram syndrome: diabetes mellitus, 
hypacusis, optic atrophy and short stature in STH deficiency]. Deutsche 
medizinische Wochenschrift 122(4):86–90. 
Hofmann S, Bezold R, Jaksch M, Obermaier-Kusser B, Mertens S, Kaufhold P, Rabl 
W, Hecker W, Gerbitz KD. 1997b. Wolfram (DIDMOAD) syndrome and Leber 
hereditary optic neuropathy (LHON) are associated with distinct mitochondrial 
DNA haplotypes. Genomics 39(1):8–18. 
Hofmann S, Philbrook C, Gerbitz KD, Bauer MF. 2003. Wolfram syndrome: structural 
and functional analyses of mutant and wild-type wolframin, the WFS1 gene product. 
Human molecular genetics 12(16):2003–2012. 
Homan MR, MacKay BR. 1987. Primary hypogonadism in two siblings with Wolfram 
syndrome. Diabetes care 10(5):664–665. 
Inoue H, Tanizawa Y, Wasson J, Behn P, Kalidas K, Bernal-Mizrachi E, Mueckler M, 
Marshall H, Donis-Keller H, Crock P, Rogers D, Mikuni M, Kumashiro H, Higashi 
K, Sobue G, Oka Y, Permutt MA. 1998. A gene encoding a transmembrane protein 
is mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome). 
Nature genetics 20(2):143–148. 
Ishihara H, Takeda S, Tamura A, Takahashi R, Yamaguchi S, Takei D, Yamada T, 
Inoue H, Soga H, Katagiri H, Tanizawa Y, Oka Y. 2004. Disruption of the WFS1 
gene in mice causes progressive beta-cell loss and impaired stimulus-secretion 
coupling in insulin secretion. Human molecular genetics 13(11):1159–1170. 
Ito S, Sakakibara R, Hattori T. 2007. Wolfram syndrome presenting marked brain MR 
imaging abnormalities with few neurologic abnormalities. AJNR American journal 
of neuroradiology 28(2):305–306. 
Jung DY, Ko HJ, Lichtman EI, Lee E, Lawton E, Ong H, Yu K, Azuma Y, Friedline 
RH, Lee KW, Kim JK. 2013. Short-term weight loss attenuates local tissue 
inflammation and improves insulin sensitivity without affecting adipose 
inflammation in obese mice. American journal of physiology Endocrinology and 
metabolism 304(9):E964–976. 
Kakiuchi C, Ishiwata M, Hayashi A, Kato T. 2006. XBP1 induces WFS1 through an 
endoplasmic reticulum stress response element-like motif in SH-SY5Y cells. Journal 
of neurochemistry 97(2):545–555. 
Karasik A, O’Hara C, Srikanta S, Swift M, Soeldner JS, Kahn CR, Herskowitz RD. 
1989. Genetically programmed selective islet beta-cell loss in diabetic subjects with 
Wolfram's syndrome. Diabetes care 12(2):135–138. 
Kato T, Ishiwata M, Yamada K, Kasahara T, Kakiuchi C, Iwamoto K, Kawamura K, 
Ishihara H, Oka Y. 2008. Behavioral and gene expression analyses of Wfs1 
knockout mice as a possible animal model of mood disorder. Neuroscience research 
61(2):143–158. 
Kawai Y, Hata T, Suzuki O, Matsuda J. 2006. The relationship between sperm 
morphology and in vitro fertilization ability in mice. The Journal of reproduction 
and development 52(4):561–568. 
15
58 
Kawano J, Fujinaga R, Yamamoto-Hanada K, Oka Y, Tanizawa Y, Shinoda K. 2009. 
Wolfram syndrome 1 (Wfs1) mRNA expression in the normal mouse brain during 
postnatal development. Neuroscience research 64(2):213–230. 
Kawano J, Tanizawa Y, Shinoda K. 2008. Wolfram syndrome 1 (Wfs1) gene expression 
in the normal mouse visual system. The Journal of comparative neurology 510(1):1–
23. 
Khanim F, Kirk J, Latif F, Barrett TG. 2001. WFS1/wolframin mutations, Wolfram 
syndrome, and associated diseases. Human mutation 17(5):357–367. 
Kinsley BT, Swift M, Dumont RH, Swift RG. 1995. Morbidity and mortality in the 
Wolfram syndrome. Diabetes care 18(12):1566–1570. 
Koks S, Soomets U, Paya-Cano JL, Fernandes C, Luuk H, Plaas M, Terasmaa A, 
Tillmann V, Noormets K, Vasar E, Schalkwyk LC. 2009. Wfs1 gene deletion causes 
growth retardation in mice and interferes with the growth hormone pathway. 
Physiological genomics 37(3):249–259. 
Kuhl J, Hilding A, Ostenson CG, Grill V, Efendic S, Bavenholm P. 2005. 
Characterisation of subjects with early abnormalities of glucose tolerance in the 
Stockholm Diabetes Prevention Programme: the impact of sex and type 2 diabetes 
heredity. Diabetologia 48(1):35–40. 
Kumar S. 2010. Wolfram syndrome: important implications for pediatricians and 
pediatric endocrinologists. Pediatric diabetes 11(1):28–37. 
Kõks S LH, Plaas M, Vasar E. 2008. Expressional profile of the wfs1 gene. In: Kõks S 
VE, ed. Emerging Link Between the Emotional Brain and Endocrine Pancreas: 
Kerala: Research Signpost. p 71–86. 
Lai E, Teodoro T, Volchuk A. 2007. Endoplasmic reticulum stress: signaling the 
unfolded protein response. Physiology 22:193–201. 
Larsen ZM, Johannesen J, Kristiansen OP, Nerup J, Pociot F, Danish IE, Genetics G, 
Danish Study Group of IiC. 2004. Evidence for linkage on chromosome 4p16.1 in 
Type 1 diabetes Danish families and complete mutation scanning of the WFS1 
(Wolframin) gene. Diabetic medicine : a journal of the British Diabetic Association 
21(3):218–222. 
Le May C, Chu K, Hu M, Ortega CS, Simpson ER, Korach KS, Tsai MJ, Mauvais-
Jarvis F. 2006. Estrogens protect pancreatic beta-cells from apoptosis and prevent 
insulin-deficient diabetes mellitus in mice. Proceedings of the National Academy of 
Sciences of the United States of America 103(24):9232–9237. 
Levi S, Cox M, Lugon M, Hodkinson M, Tomkins A. 1990. Increased energy 
expenditure in Parkinson’s disease. Bmj 301(6763):1256–1257. 
Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. 2000. Peroxisome 
proliferator-activated receptor gamma ligands inhibit development of atherosclerosis 
in LDL receptor-deficient mice. The Journal of clinical investigation 106(4):523–
531. 
Liu S, Le May C, Wong WP, Ward RD, Clegg DJ, Marcelli M, Korach KS, Mauvais-
Jarvis F. 2009. Importance of extranuclear estrogen receptor-alpha and membrane G 
protein-coupled estrogen receptor in pancreatic islet survival. Diabetes 58(10):2292–
2302. 
Liu S, Mauvais-Jarvis F. 2010. Minireview: Estrogenic protection of beta-cell failure in 
metabolic diseases. Endocrinology 151(3):859–864. 
Louet JF, LeMay C, Mauvais-Jarvis F. 2004. Antidiabetic actions of estrogen: insight 
from human and genetic mouse models. Current atherosclerosis reports 6(3):180–
185. 
59 
Luuk H, Koks S, Plaas M, Hannibal J, Rehfeld JF, Vasar E. 2008. Distribution of Wfs1 
protein in the central nervous system of the mouse and its relation to clinical 
symptoms of the Wolfram syndrome. The Journal of comparative neurology 
509(6):642–660. 
Luuk H, Plaas M, Raud S, Innos J, Sutt S, Lasner H, Abramov U, Kurrikoff K, Koks S, 
Vasar E. 2009. Wfs1-deficient mice display impaired behavioural adaptation in 
stressful environment. Behavioural brain research 198(2):334–345. 
Macotela Y, Boucher J, Tran TT, Kahn CR. 2009. Sex and depot differences in 
adipocyte insulin sensitivity and glucose metabolism. Diabetes 58(4):803–812. 
Markus HS, Cox M, Tomkins AM. 1992. Raised resting energy expenditure in 
Parkinson’s disease and its relationship to muscle rigidity. Clinical science 
83(2):199–204. 
Marshall BA, Permutt MA, Paciorkowski AR, Hoekel J, Karzon R, Wasson J, Viehover 
A, White NH, Shimony JS, Manwaring L, Austin P, Hullar TE, Hershey T, The 
Washington University Wolfram Study Group W. 2013. Phenotypic characteristics 
of early Wolfram syndrome. Orphanet journal of rare diseases 8(1):64. 
Martin B, Golden E, Carlson OD, Pistell P, Zhou J, Kim W, Frank BP, Thomas S, 
Chadwick WA, Greig NH, Bates GP, Sathasivam K, Bernier M, Maudsley S, 
Mattson MP, Egan JM. 2009. Exendin-4 improves glycemic control, ameliorates 
brain and pancreatic pathologies, and extends survival in a mouse model of 
Huntington's disease. Diabetes 58(2):318–328. 
Mauer J, Chaurasia B, Plum L, Quast T, Hampel B, Bluher M, Kolanus W, Kahn CR, 
Bruning JC. 2010. Myeloid cell-restricted insulin receptor deficiency protects 
against obesity-induced inflammation and systemic insulin resistance. PLoS genetics 
6(5):e1000938. 
McLachlan SM, Lu L, Aliesky HA, Williams RW, Rapoport B. 2011. Distinct genetic 
signatures for variability in total and free serum thyroxine levels in four sets of 
recombinant inbred mice. Endocrinology 152(3):1172–1179. 
Medlej R, Wasson J, Baz P, Azar S, Salti I, Loiselet J, Permutt A, Halaby G. 2004. 
Diabetes mellitus and optic atrophy: a study of Wolfram syndrome in the Lebanese 
population. The Journal of clinical endocrinology and metabolism 89(4):1656–1661. 
Mittendorfer B. 2005. Insulin resistance: sex matters. Current opinion in clinical 
nutrition and metabolic care 8(4):367–372. 
Morales LM, Estevez J, Suarez H, Villalobos R, Chacin de Bonilla L, Bonilla E. 1989. 
Nutritional evaluation of Huntington disease patients. The American journal of 
clinical nutrition 50(1):145–150. 
Nakamura A, Shimizu C, Nagai S, Taniguchi S, Umetsu M, Atsumi T, Wada N, 
Yoshioka N, Ono Y, Tanizawa Y, Koike T. 2006. A novel mutation of WFS1 gene 
in a Japanese man of Wolfram syndrome with positive diabetes-related antibodies. 
Diabetes research and clinical practice 73(2):215–217. 
Noormets K, Koks S, Muldmaa M, Mauring L, Vasar E, Tillmann V. 2011. Sex 
differences in the development of diabetes in mice with deleted wolframin (Wfs1) 
gene. Experimental and clinical endocrinology & diabetes 119(5):271–275. 
Ohata T, Koizumi A, Kayo T, Shoji Y, Watanabe A, Monoh K, Higashi K, Ito S, 
Ogawa O, Wada Y, Takada G. 1998. Evidence of an increased risk of hearing loss in 
heterozygous carriers in a Wolfram syndrome family. Human genetics 103(4):470–
474. 
60 
Olsson T, Nasman B, Rasmuson S, Ahren B. 1998. Dual relation between leptin and 
cortisol in humans is disturbed in Alzheimer’s disease. Biological psychiatry 
44(5):374–376. 
Osman AA, Saito M, Makepeace C, Permutt MA, Schlesinger P, Mueckler M. 2003. 
Wolframin expression induces novel ion channel activity in endoplasmic reticulum 
membranes and increases intracellular calcium. The Journal of biological chemistry 
278(52):52755–52762. 
Pakdemirli E, Karabulut N, Bir LS, Sermez Y. 2005. Cranial magnetic resonance 
imaging of Wolfram (DIDMOAD) syndrome. Australasian radiology 49(2):189–
191. 
Peden NR, Gay JD, Jung RT, Kuwayti K. 1986. Wolfram (DIDMOAD) syndrome: a 
complex long-term problem in management. The Quarterly journal of medicine 
58(226):167–180. 
Pennings RJ, Huygen PL, van den Ouweland JM, Cryns K, Dikkeschei LD, Van Camp 
G, Cremers CW. 2004. Sex-related hearing impairment in Wolfram syndrome 
patients identified by inactivating WFS1 mutations. Audiology & neuro-otology 
9(1):51–62. 
Pick A, Clark J, Kubstrup C, Levisetti M, Pugh W, Bonner-Weir S, Polonsky KS. 1998. 
Role of apoptosis in failure of beta-cell mass compensation for insulin resistance 
and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes 47(3):358–364. 
Plantinga RF, Pennings RJ, Huygen PL, Bruno R, Eller P, Barrett TG, Vialettes B, 
Paquis-Fluklinger V, Lombardo F, Cremers CW. 2008. Hearing impairment in 
genotyped Wolfram syndrome patients. The Annals of otology, rhinology, and 
laryngology 117(7):494–500. 
Pohlenz J, Maqueem A, Cua K, Weiss RE, Van Sande J, Refetoff S. 1999. Improved 
radioimmunoassay for measurement of mouse thyrotropin in serum: strain 
differences in thyrotropin concentration and thyrotroph sensitivity to thyroid 
hormone. Thyroid: official journal of the American Thyroid Association 
9(12):1265–1271. 
Popovic V, Svetel M, Djurovic M, Petrovic S, Doknic M, Pekic S, Miljic D, Milic N, 
Glodic J, Dieguez C, Casanueva FF, Kostic V. 2004. Circulating and cerebrospinal 
fluid ghrelin and leptin: potential role in altered body weight in Huntington's 
disease. European journal of endocrinology / European Federation of Endocrine 
Societies 151(4):451–455. 
Power DA, Noel J, Collins R, O'Neill D. 2001. Circulating leptin levels and weight loss 
in Alzheimer's disease patients. Dementia and geriatric cognitive disorders 
12(2):167–170. 
Pratley RE, Salbe AD, Ravussin E, Caviness JN. 2000. Higher sedentary energy 
expenditure in patients with Huntington's disease. Annals of neurology 47(1):64–70. 
Rando TA, Horton JC, Layzer RB. 1992. Wolfram syndrome: evidence of a diffuse 
neurodegenerative disease by magnetic resonance imaging. Neurology 42(6):1220–
1224. 
Raymond NT, Langley JD, Goyder E, Botha JL, Burden AC, Hearnshaw JR. 1995. 
Insulin treated diabetes mellitus: causes of death determined from record linkage of 
population based registers in Leicestershire, UK. Journal of epidemiology and 
community health 49(6):570–574. 
Riggs AC, Bernal-Mizrachi E, Ohsugi M, Wasson J, Fatrai S, Welling C, Murray J, 
Schmidt RE, Herrera PL, Permutt MA. 2005. Mice conditionally lacking the 
61 
Wolfram gene in pancreatic islet beta cells exhibit diabetes as a result of enhanced 
endoplasmic reticulum stress and apoptosis. Diabetologia 48(11):2313–2321. 
Rigoli L, Lombardo F, Di Bella C. 2011. Wolfram syndrome and WFS1 gene. Clinical 
genetics 79(2):103–117. 
Rohayem J, Ehlers C, Wiedemann B, Holl R, Oexle K, Kordonouri O, Salzano G, 
Meissner T, Burger W, Schober E, Huebner A, Lee-Kirsch MA, Wolfram Syndrome 
Diabetes Writing G. 2011. Diabetes and neurodegeneration in Wolfram syndrome: a 
multicenter study of phenotype and genotype. Diabetes care 34(7):1503–1510. 
Rotig A, Cormier V, Chatelain P, Francois R, Saudubray JM, Rustin P, Munnich A. 
1993. Deletion of mitochondrial DNA in a case of early-onset diabetes mellitus, 
optic atrophy, and deafness (Wolfram syndrome, MIM 222300). The Journal of 
clinical investigation 91(3):1095–1098. 
Sandhu MS, Weedon MN, Fawcett KA, Wasson J, Debenham SL, Daly A, Lango H, 
Frayling TM, Neumann RJ, Sherva R, Blech I, Pharoah PD, Palmer CN, Kimber C, 
Tavendale R, Morris AD, McCarthy MI, Walker M, Hitman G, Glaser B, Permutt 
MA, Hattersley AT, Wareham NJ, Barroso I. 2007. Common variants in WFS1 
confer risk of type 2 diabetes. Nature genetics 39(8):951–953. 
Schalkwyk LC, Fernandes C, Nash MW, Kurrikoff K, Vasar E, Koks S. 2007. 
Interpretation of knockout experiments: the congenic footprint. Genes, brain, and 
behavior 6(3):299–303. 
Schmidt-Kastner R, Kreczmanski P, Preising M, Diederen R, Schmitz C, Reis D, 
Blanks J, Dorey CK. 2009. Expression of the diabetes risk gene wolframin (WFS1) 
in the human retina. Experimental eye research 89(4):568–574. 
Scolding NJ, Kellar-Wood HF, Shaw C, Shneerson JM, Antoun N. 1996. Wolfram 
syndrome: hereditary diabetes mellitus with brainstem and optic atrophy. Annals of 
neurology 39(3):352–360. 
Sequeira A, Kim C, Seguin M, Lesage A, Chawky N, Desautels A, Tousignant M, 
Vanier C, Lipp O, Benkelfat C, Rouleau G, Turecki G. 2003. Wolfram syndrome 
and suicide: Evidence for a role of WFS1 in suicidal and impulsive behavior. 
American journal of medical genetics Part B, Neuropsychiatric genetics : the official 
publication of the International Society of Psychiatric Genetics 119B(1):108–113. 
Simsek E, Simsek T, Tekgul S, Hosal S, Seyrantepe V, Aktan G. 2003. Wolfram 
(DIDMOAD) syndrome: a multidisciplinary clinical study in nine Turkish patients 
and review of the literature. Acta paediatrica 92(1):55–61. 
Smith CJ, Crock PA, King BR, Meldrum CJ, Scott RJ. 2004. Phenotype-genotype 
correlations in a series of wolfram syndrome families. Diabetes care 27(8):2003–
2009. 
Soliman AT, Bappal B, Darwish A, Rajab A, Asfour M. 1995. Growth hormone 
deficiency and empty sella in DIDMOAD syndrome: an endocrine study. Archives 
of disease in childhood 73(3):251–253. 
Sparso T, Andersen G, Albrechtsen A, Jorgensen T, Borch-Johnsen K, Sandbaek A, 
Lauritzen T, Wasson J, Permutt MA, Glaser B, Madsbad S, Pedersen O, Hansen T. 
2008. Impact of polymorphisms in WFS1 on prediabetic phenotypes in a 
population-based sample of middle-aged people with normal and abnormal glucose 
regulation. Diabetologia 51(9):1646–1652. 
Stoy N, McKay E. 2000. Weight loss in Huntington's disease. Annals of neurology 
48(1):130–131. 
Strom TM, Hortnagel K, Hofmann S, Gekeler F, Scharfe C, Rabl W, Gerbitz KD, 
Meitinger T. 1998. Diabetes insipidus, diabetes mellitus, optic atrophy and deafness 
16
62 
(DIDMOAD) caused by mutations in a novel gene (wolframin) coding for a 
predicted transmembrane protein. Human molecular genetics 7(13):2021–2028. 
Swift RG, Polymeropoulos MH, Torres R, Swift M. 1998. Predisposition of Wolfram 
syndrome heterozygotes to psychiatric illness. Molecular psychiatry 3(1):86–91. 
Swift RG, Sadler DB, Swift M. 1990. Psychiatric findings in Wolfram syndrome 
homozygotes. Lancet 336(8716):667–669. 
Zhu M, Mizuno A, Kuwajima M, Ogino T, Murakami T, Noma Y, Sano T, Shima K. 
1998. Ovarian hormone-induced beta-cell hypertrophy contributes to the 
homeostatic control of beta-cell mass in OLETF female rat, a model of Type II 
diabetes. Diabetologia 41(7):799–805. 
Zierath JR, Houseknecht KL, Gnudi L, Kahn BB. 1997. High-fat feeding impairs 
insulin-stimulated GLUT4 recruitment via an early insulin-signaling defect. 
Diabetes 46(2):215–223. 
Takeda K, Inoue H, Tanizawa Y, Matsuzaki Y, Oba J, Watanabe Y, Shinoda K, Oka Y. 
2001. WFS1 (Wolfram syndrome 1) gene product: predominant subcellular loca-
lization to endoplasmic reticulum in cultured cells and neuronal expression in rat 
brain. Human molecular genetics 10(5):477–484. 
Tranebjaerg L, Barrett T, Rendtorff ND. 1993. WFS1-Related Disorders. In: Pagon RA, 
Adam MP, Bird TD, Dolan CR, Fong CT, Smith RJH, Stephens K, eds. 
GeneReviews. Seattle (WA). 
Trejo A, Tarrats RM, Alonso ME, Boll MC, Ochoa A, Velasquez L. 2004. Assessment 
of the nutrition status of patients with Huntington's disease. Nutrition 20(2):192–
196. 
Ueda K, Kawano J, Takeda K, Yujiri T, Tanabe K, Anno T, Akiyama M, Nozaki J, 
Yoshinaga T, Koizumi A, Shinoda K, Oka Y, Tanizawa Y. 2005. Endoplasmic 
reticulum stress induces Wfs1 gene expression in pancreatic beta-cells via 
transcriptional activation. European journal of endocrinology / European Federation 
of Endocrine Societies 153(1):167–176. 
Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, Fishel MA, 
Kulstad JJ, Green PS, Cook DG, Kahn SE, Keeling ML, Craft S. 2005. Preserved 
cognition in patients with early Alzheimer disease and amnestic mild cognitive 
impairment during treatment with rosiglitazone: a preliminary study. The American 
journal of geriatric psychiatry : official journal of the American Association for 
Geriatric Psychiatry 13(11):950–958. 
Vendrell J, Ercilla G, Faundez A, Soler S, Gutierrez C, Gomis R, Vilardell E, Richart C. 
1994. Analysis of the contribution of the HLA system to the inheritance in the 
Wolfram syndrome. Diabetes research and clinical practice 22(2–3):175–180. 
Wolfram D, Wagener H. 1938. Diabetes mellitus and simple optic atrophy among 
siblings: report of four cases. Mayo Clin Proc 13:715–718. 
Yamada T, Ishihara H, Tamura A, Takahashi R, Yamaguchi S, Takei D, Tokita A, 
Satake C, Tashiro F, Katagiri H, Aburatani H, Miyazaki J, Oka Y. 2006. WFS1-
deficiency increases endoplasmic reticulum stress, impairs cell cycle progression 
and triggers the apoptotic pathway specifically in pancreatic beta-cells. Human 
molecular genetics 15(10):1600–1609. 
Yamamoto H, Hofmann S, Hamasaki DI, Yamamoto H, Kreczmanski P, Schmitz C, 
Parel JM, Schmidt-Kastner R. 2006. Wolfram syndrome 1 (WFS1) protein 
expression in retinal ganglion cells and optic nerve glia of the cynomolgus monkey. 
Experimental eye research 83(5):1303–1306. 
63 
Yan J, Takahashi T, Ohura T, Adachi H, Takahashi I, Ogawa E, Okuda H, Kobayashi 
H, Hitomi T, Liu W, Harada KH, Koizumi A. 2013. Combined linkage analysis and 
exome sequencing identifies novel genes for familial goiter. Journal of human 
genetics 58(6):366–377. 
Young TL, Ives E, Lynch E, Person R, Snook S, MacLaren L, Cater T, Griffin A, 
Fernandez B, Lee MK, King MC. 2001. Non-syndromic progressive hearing loss 
DFNA38 is caused by heterozygous missense mutation in the Wolfram syndrome 






SUMMARY IN ESTONIAN 
Diabeedi kujunemine, fertiilsuse ja  
energia ainevahetuse häired Wfs1 puudulikkusega hiirel  
kui Wolframi sündroomi loommudelil 
Wolframi sündroom (WS) on tuntud ka akronüümi DIDMOAD (Diabetes 
Insipidus, Diabetes Mellitus, Optic Atrophy and Deafness) nime all. Antud 
sündroomi kirjeldasid esmakordselt Wolfram ja Wagener 1938. aastal. See on 
autosoom-retsessiivse pärandumismustriga haigus, mille peamisteks kliini-
listeks avaldusteks on varases lapseeas algav 1. tüüpi diabeet, nägemisnärvi 
atroofia, magediabeet ja sensorineuraalne kuulmislangus (Wolfram ja Wagener, 
1938; Barrett ja Bundey, 1997; Smith jt, 2004). Lisaks võivad esineda ka 
urotrakti väärarendid, mitmed erinevad neuroloogilised ning psühhiaatrilised 
probleemid (Peden jt, 1986; Barrett jt, 1995; Barrett ja Bundey, 1997; Medlej jt, 
2004).  
Wolframi sündroomi põhjuseks on WFS1 geeni mutatsioon, mis paikneb 4. 
kromosoomi lühikeses õlas (4p16) (Collier jt, 1996). Seni on kirjeldatud ligi 
200 erinevat geenimutatsiooni (de Heredia jt, 2013). WFS1 geen toodab 
volframiini. See on endoplasmaatilise retiikulumi (ER) koosseisus olev glüko-
proteiin, mis omab olulist rolli ER stressi ja raku apoptoosi väljakujunemisel 
(Fonseca jt, 2005; Riggs jt, 2005; Yamada jt, 2006).  
Esimeseks kliiniliseks avalduseks WS korral on diabeet. Diabeet tekib WS 
haigetel keskmiselt 6-aastaselt (Barrett jt, 1995; Kinsley jt, 1995; Medlej jt, 
2004), poistel pisut varem kui tüdrukutel (Hardy jt, 1999; Smith jt, 2004; 
Marshall jt, 2013). Võrreldes 1. tüüpi diabeediga esineb Wolframi sündroomiga 
patsientidel vähem mikrovaskulaarseid komplikatsioone, ketoatsidoosi ja ka 
insuliini vajadus on väiksem (Peden jt, 1986; Barrett jt, 1995; Kinsley jt, 1995; 
Cano jt 2007a).  
Täpne diabeedi tekkemehhanism WS korral ei ole teada. Seda on seostatud 
ER stressiga, mis põhjustab pankrease β-rakkude apoptoosi ja sellest tuleneva 
insuliini puudulikkuse (Ishihara jt, 2004; Riggs jt, 2005). On teada ka, et WS-ga 
patsientidel võib esineda prohormooni konvertaasi (PC) puudulikkust, mille 
tulemusel ei toodeta inaktiivsetest hormoonide eelvormidest bioloogiliselt 
aktiivseid hormoone (Gabreels jt, 1998). Meile teadaolevalt ei ole seni 
proinsuliini (insuliini eellashormooni) taset WS korral uuritud. 
Sageli kaasub WS-ga lühike kasv (Hofmann jt, 1997a; Simsek jt, 2003; 
Medlej jt, 2004; Ganie jt, 2011), mille üheks põhjuseks on leitud kasvu-
hormooni puudulikkus (Barrett jt, 1995; Barrett ja Bundey, 1997; Kõks jt, 
2009). Siiani puudub info WS-ga patsientide fertiilsusest. Varasemalt on 
kirjeldatud häirunud hüpofüüsi funktsiooni (Medlej jt, 2004) ja meeste puhul ka 
primaarset gonaadide atroofiat koos hüpergonadotroopse hüpogonadismiga 
(Peden jt, 1986; Barrett ja Bundey, 1997; Medlej jt, 2004). Meile teadaolevalt ei 
ole siiani uuritud WFS1 geeni rolli fertiilsuse mõjutamisel. 
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Patsientidel, kellel esineb WS, on kirjeldatud häirunud kilpnäärme 
funktsiooni, kuid tegemist on vaid üksikute kirjeldustega (Tranebjaerg jt, 1993; 
Hildebrand jt, 2008; Yan jt, 2013).  
Hiljuti avaldatud andmed on näidanud, et erinevate neurodegeneratiivsete 
haiguste (nt Alzheimeri tõbi, Parkinsoni tõbi või Huntingtoni tõbi) korral häirub 
patsientidel ainevahetus, kujunevad kaaluprobleemid, veresuhkru ja leptiini 
ainevahetuse häired jms (Cai jt, 2012). Kuna WS on peetud ka neuro-
degeneratiivseks haiguseks, võiksime oodata sarnaseid ainevahetusprobleeme 
ka antud haigusega patsientidel.  
Tartu Ülikoolis on loodud WS loommudel – Wfs1 puudulikkusega hiir. 
  
Uurimistöö eesmärgid 
Antud uurimistöö eesmärgiks oli välja selgitada, kas isaste Wfs1 puudu-
likkusega hiirte (Wfs1KO) viljakus võrreldes tervete hiirtega on muutunud ja 
kui see on nii, siis püüda leida selle põhjusi. Lisaks soovisime kirjeldada 
diabeedi kujunemist vanuselises ja sugude lõikes ning mõõta neil loomadel 
proinsuliini ja insuliini taset. Soovisime kirjeldada ka võimaliku kasvuhäire 
kujunemist, leida selle põhjusi ning uurida energia ainevahetust Wfs1 
puudulikkusega hiirtel.  
 
Uuringu metoodika ja katseloomad 
Uuringutes kasutati Tartu Ülikooli teadlaste poolt loodud Wfs1-puudulikkusega 
hiiri. Kasutati ainult homosügootseid hiiri ja nende metsik-tüüpi (ilma 
mutatsioonita – wt) pesakonnakaaslasi. Kokku kasutati käesoleva töö läbi-
viimiseks 142 Wfs1KO hiirt ja 306 metsik-tüüpi hiirt. Loomad asusid 
konstantsetes laboritingimustes, kus oli 12-tunnine pimeduse ja valguse tsükkel. 
Kõigil hiirtel oli ööpäevaringselt vaba juurdepääs veele ja toidule. Kõik 
loomadega läbiviidud protseduurid olid kooskõlas EU direktiiviga 86/609/EEC 
ja nende läbiviimiseks oli olemas Eesti Loomkatsekomisjoni luba (number 86, 
28.08.2007). 
 
1. Viljakuse uuring (1. artikkel) 
Kaheksa- kuni kaheteistkümnenädalased isased hiired (13 Wfs1KO ja 13 wt) 
pandi ühte puuri kokku kahe emase wt hiirega. Hiired viibisid ühes puuris kolm 
ööpäeva või kuni emashiirtel oli sedastatav vaginaalse korgi olemasolu 
(indikaator paaritumisest). Ühe isase juurde pandi uuringu vältel kuus erinevat 
emashiirt. Emased hiired kaaluti iganädalaselt ja kaalutõusu omavad hiired 
(eeldatavasti tiined hiired) asetati üksikpuuridesse, kus nad poegisid. 
Viljakusemäär (mitu emast hiirt suutis üks isane viljastada) ja poegade arv 




2. Veresuhkru mõõtmised (2. artikkel) 
Uuring teostati üheksanädalaste hiirtega (igas grupis 21 hiirt: mõlemast soost 
Wfs1KO ja wt hiired). Kuni 20. elunädalani mõõdeti glükomeetriga hiirte 
sabaveenist iganädalaselt hommikune veresuhkru tase (paastu ei rakendatud). 
Alates 20. elunädalast mõõdeti veresuhkrut iga kahe nädala tagant. 30. 
elunädalal viidi hiirtel läbi intraperitoneaalne glükoosi tolerantsuse test. Selleks 
olid hiired 16 tundi söömata. Seejärel nad kaaluti ning mõõdeti nende vere-
suhkru tase (0‘). Hiirtele manustati intraperitoneaalselt glükoosilahust (arvestus-
likult 2g glükoosi kilogrammi kehamassi kohta). 60 ja 120 minuti järel mõõdeti 
veresuhkru tasemeid uuesti (vastavalt 60’ ja 120'). 
 
3. Kasvamise hindamine (2. artikkel) 
Paralleelselt veresuhkru taseme mõõtmistega hiired ka kaaluti. Nende andmete 
põhjal arvutati välja:  
‒ maksimaalne kaaluiive uuringu raames 
‒ kaaluiive 9. – 32. elunädalani 
‒ vahe maksimaalse kaalu ja 32. elunädala kaalu vahel. 
 
4. Energia ainevahetuse hindamine (3. artikkel) 
Hiired eraldati puurikaaslastest ja paigutati kolmeks nädalaks üksikpuuridesse. 
Kohanemisperioodi järgselt paigutati hiired üksi spetsiaalsesse metaboolsesse 
puuri. 48 tunni möödudes viidi hiired taas oma kodupuuridesse (üksikpuur) ja 
võimaldati neile ühe nädala pikkune taastumisperiood. Sellist harjutamist 
teostati kolmel korral. Viimase metaboolses puuris viibimise ajal mõõdeti 
järgmised energia ainevahetuse parameetrid: toidu- ja veetarve, keskmine 
hapnikutarve, soojuse ja süsihappegaasi produktsioon ning looma liikumised 
kolmes erinevas suunas (X-, Y- ja Z-teljel). 
 
5. Vereseerumi hormoonide mõõtmised (1.; 2.; ja 3. artikkel) 
Veri hormoonuuringuteks võeti hiirtelt peale nende eutaniseerimist. Vere-
proovid tsentrifuugiti, eraldati plasma ja proove analüüsiti erinevate ELISA 
kittide abil. Kõik tehnilised protseduurid teostati vastavalt iga individuaalse kiti 
kasutusjuhendile. Proovide optiline tihedus mõõdeti ELISA lugeri abil.  
 
6. Histoloogilised ja morfoloogilised uuringud (1. ja 3. artikkel) 
6.1. Sperma morfoloogia ja testiste histoloogia (1. artikkel) 
Uuringus kasutati spermat, mis oli eraldatud eelnevalt eutaniseeritud isahiirte 
munandimanuste sabaosast. Ühe isashiire kohta analüüsiti 200 spermatosoidi. 
Spermatosoidide liikuvust hinnati ja salvestati spetsiaalse mikroskoobi abil 
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(CASA) ning arvutati liikuvate ja otse liikuvate spermide osa kõigist 
spermidest. Lisaks uuriti fikseeritud proove mikroskoobi all ja hinnati 
spermatosoidide morfoloogilisi tunnuseid. Hinnatavate tunnuste aluseks võeti 
Kawai 2006. a artiklis kasutatud metoodika (Kawai jt, 2006).  
Lisaks eelpooltoodule hinnati kolme Wfs1KO ja kolme wt isashiire testiseid. 
Proovid fikseeriti parafiinis ja lõike hinnati valgusmikroskoobi all. Hindamine 
viidi läbi kahe hindaja poolt. 
 
6.2. Kilpnäärmete histoloogia (3. artikkel) 
Kilpnäärmete histoloogia hinnati viiel Wfs1KO hiirel ja seitsmel wt hiirel. Kõik 
hiired olid 17–20 nädalat vanad. Hiired eutaniseeriti ja kilpnäärmed prepa-
reeriti. Koed fikseeriti formaliinis ja säilitati parafiiniblokkides. Lõigud värviti 
hematoksüliin-eosiini ja van Gieson’i meetodeid kasutades ning morfoloogiat 
hinnati valgusmikroskoobi all. Hinnangud on teostatud kahe objektiivse hindaja 
poolt.  
 
Uurimistöö peamised tulemused 
Esimeses uuringus leidsime, et Wfs1KO isashiirtega paaritatud emashiirte 
tiinestumismäär oli madalam kui wt isashiirtega paaritatud emaste oma (15% 
vs. 32%, p<0.05). Kolmeteistkümnest Wfs1KO isashiirest viis ei suutnud 
viljastada mitte ühtegi kuuest emasest, samas kui kontrollgrupis oli igal 
isashiirel vähemalt üks pesakond (p<0.05). Pesakonna suurustes statistilisi 
erinevusi Wfs1KO ja wt isaste vahel ei esinenud. Ilmnes, et ka vaginaalseid 
korke (mis annab võimaluse hinnata aset leidnud paaritumist) oli Wfs1KO 
isashiirtega koos elanud emashiirtel tunduvalt vähem kui wt isashiirtega 
paaritatud emastel.  
Sperma liikuvus ei ole Wfs1KO isashiirtel häirunud. Ilmnes, et Wfs1KO 
isashiirte spermidel on vähem proksimaalseid keerde ja vähem ka ebahariliku 
morfoloogiaga spermi päid, mis on mõlemad seotud suhteliselt madala sperma 
viljastamisvõimega. Wfs1KO isashiirte spermidel esines ka rohkem tsütoplasma 
tilgakesi, mis on samuti seotud madala sperma viljastumisvõimekusega (Kawai 
jt, 2006). Antud erinevus ei olnud siiski võrreldes wt-grupiga statistiliselt 
oluline.  
Testiste histoloogiline uuring tõi esile seemnetorukeste epiteeli tavapärase 
ehituse puudumise Wfs1KO hiirtel. Samuti esines seemnetorukeste epiteelil 
oluliselt vähem spermatogoone ja Sertoli rakke, mis võib viia vähenenud 
spermatosoidide produktsioonini.  
Suguhormoonide (testosterooni ja FSH) tasemes ei esinenud erinevusi 
Wfs1KO ja wt isashiirte gruppide vahel.  
Teises uuringus hindasime hiirte longitudinaalset kasvu ja veresuhkru 
väärtusi erinevas vanuses. Leidsime, et Wfs1KO isashiired olid oma wt pesa-
konnakaaslastest tunduvalt kergemad juba uuringu algul (üheksanädalaselt), 
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kuid emashiirtel kujunes kaaluvahe välja alles 16 nädala vanuselt. Samuti 
hakkasid Wfs1KO hiired uuringu viimastel nädalatel kaotama oma kehamassi. 
Veresuhkru väärtustes tekkis statistiline erinevus 24. elunädalal, kui Wfs1KO 
isashiirte veresuhkur tõusis oluliselt kõrgemaks kui wt hiirtel. 32. nädalal oli 
keskmine veresuhkru tase isastel Wfs1KO hiirtel 9.4 mmol/l võrrelduna 7.9 
mmol/l wt isastel hiirtel (p<0.05). Üllatuslikult leidsime, et emashiirtel esinesid 
vastupidised muutused: emastel Wfs1KO hiirtel olid veresuhkru tasemed 
madalamad kui wt hiirtel. Sellele vaatamata ilmnes nii Wfs1KO isas- kui 
emashiirtel 30. elunädalal väljendunud glükoosi tolerantsi häire. Kuigi hiirtel 
puuduvad kindlad kriteeriumid diabeedi diagnoosimiseks, oli isashiirtel 
tõenäoliselt tegemist juba väljakujunenud diabeediga. 
Isaste Wfs1KO hiirte insuliini tase oli tunduvalt madalam kui wt isas-
loomadel ja Wfs1KO emasloomadel. Samas ilmnes, et Wfs1KO isasloomadel 
esines kõrgem proinsuliini taseme ja proinsuliini/insuliini suhe kui wt isastel. 
Need tulemused näitavad, et diabeedi tekkepõhjuseks Wfs1KO hiirtel pole mitte 
niivõrd primaarselt insuliini defitsiit, kuivõrd võimetus konverteerida mitte-
aktiivset proinsuliini aktiivseks insuliiniks.  
Kolmanda uuringu raames mõõtsime erinevaid energia ainevahetuse para-
meetreid. Leidsime, et WfsKO hiirte energia ainevahetus ei erinenud oluliselt 
wt hiirte omast. Küll olid aga olulised erinevused sugude vahel. Emaste hiirte 
hapnikutarve oli kõrgem kui isashiirtel, samuti produtseerisid nad võrreldes 
isashiirtega rohkem süsihappegaasi ja soojust. Need muutused olid sarnased 
mõlema genotüübi siseselt. Wfs1KO isashiired sõid oma kehakaalu kohta 
tunduvalt vähem ja kaotasid eksperimendi vältel tunduvalt rohkem oma keha-
kaalus kui wt isased. Isastel Wfs1KO hiirtel leiti madalam plasma leptiini tase 
kui wt hiirtel. Emasloomadel sellist erinevust ei leitud, mis võib viidata 
võimalikule leptiini resistentsusele Wfs1KO emashiirtel. 
 
Järeldused 
1. Wfs1KO isashiirte viljakus, võrreldes wt isashiirtega, on langenud. See on 
tingitud muutustest sperma ja testiste morfoloogias.  
2. Wfs1KO isashiirte spermidel on vähem proksimaalselt keerdunud sabasid ja 
ebaharilikke päid, mis mõlemad seostuvad madalama viljastumisvõimega. 
Wfs1KO isashiirte seemnetorukestel puudub tavapärane epiteel ning esineb 
spermatogoonide ja Sertoli rakkude vähenemine, mis võib põhjustada 
langenud sperma produktsiooni.  
3. Kasvuhäire ja diabeedi kujunemisel esinevad tõsised sugudevahelised 
erinevused. Kasvuhäire on Wfs1KO isashiirtel väljendunud juba sünnil, 
kusjuures emashiirtel kujuneb see alles esimeste elukuude jooksul. Mõle-
mast soost Wfs1KO hiirtel esineb väljendunud glükoosi tolerantsuse häire, 
kuid väljendunud diabeet koos madala plasma insuliini tasemega kujuneb 
ainult isashiirtel.  
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4. Leidsime esmakordselt, et üheks põhjuseks, miks Wfs1KO isashiirtel 
kujuneb diabeet, ei ole primaarsena mitte insuliini defitsiitsus, kuivõrd 
võimetus konverteerida mitteaktiivset proinsuliini aktiivseks insuliiniks. 
Selle leiu kinnituseks on ka hiljem teiste uurimisgruppide poolt avaldatud 
andmed tõusnud proinsuliini/insuliini tasemete kohta.  
5. Energia ainevahetuses ei esine olulisi erinevusi Wfs1KO ja wt hiirte vahel. 
Küll aga leidsime, et emastel hiirtel, nii Wfs1KO kui ka wt grupis, on 
madalam plasma türoksiini tase kui isashiirtel. Meie tulemused viitavad ka 
võimalikule leptiini resistentsusele Wfs1KO emasloomadel, mille tõesta-
mine vajab aga täiendavaid uuringuid.  




This study was carried out at the Department of Physiology of the Tartu 
University. The research was financially supported by Estonian Science 
Foundation Grants No. 7295 and 7479, by targeted financial support from the 
Estonian Ministry of Education and Research (TARLA 2695) and by the 
European Union through the European Regional Developmental Fund. 
Conducting and finishing the studies and this thesis is a result of teamwork 
and there have been really many important people to whom I would like to 
express my deepest gratitude. 
 
Most of the all I would like to thank my supervisors 
– Professor Vallo Tillmann for giving me the opportunity to perform this 
research, for the persistent and constructive guidance throughout the years 
and for the sharp ideas that helped me to see the clinical values and 
outcomes of a laboratory work that helped me not to drift off the course. 
– Professor Sulev Kõks for his everlasting enthusiasm, energy, support and 
time he always had for me. He has given me the original impression and idea 
how the science should be done and taught me to deeply respect the 
preclinical research. My special gratitude goes for him for the positivity, 
encouragement and belief he had in me, even if everything seemed to be 
falling apart.  
 
I am very grateful for professor Vallo Volke and professor Andres Salumets for 
reviewing the thesis. The constructive and professional criticism and the 
suggestions that were made had a great value.  
This work would never have been possible without the help and contribution 
of my co-authors and co-workers at the laboratory. I would like to address my 
deepest gratitude to 
‒ Professor Eero Vasar for the constructive criticism and suggestions in 
reviewing the original papers and giving the valuable ideas for proceeding.  
‒ Mario Plaas for generating the Wfs1KO mice used in all the experiments. 
‒ Marilin Ivask and Kaido Kurrikoff for conducting the procedures with the 
animals for which I had no sufficient skills.  
‒ Aivi Keldrimaa, Mari Muldmaa and Laura Mauring for helping me to carry 
on the experiments in the time my daughter was born and needed me the 
most.  
‒ Professor Ants Kavak for investigating the sperm of the mice and 
conducting the analysis of the fertility experiments.  
‒ Professor Marina Aunapuu and professor Andres Arend for the histological 
investigations of the testes and thyroid glands of the mice. I especially thank 
prof Aunapuu for the patience she had when we struggled with separating 
the thyroid glands of the mice.  
‒ Pille Kool for helping with the statistical analyses.  
71 
‒ All the wonderful colleagues in the laboratory of Department of Physiology 
who never hesitated in helping when it was needed.  
 
I am very thankful to the great amount of colleagues and friends whose help has 
been remarkable. 
‒ I am very thankful for all my supervisors during my residency studies for the 
support and understanding when I tried to do several things at one time. My 
deepest gratitude belongs to associate professor Tuuli Metsvaht, associate 
professor Inga Talvik and dr Sirje Mikkel who provided me some free time 
to write my papers and finish the thesis.  
‒ I am grateful to Mrs Tiina Vinni, the secretary of the Department of 
Paediatrics for revising the Estonian version of the thesis. She has also been 
really helpful with all kind of paperwork during my studies. 
‒ I thank Tuuli Ruus and Halja Suss for their patience and guidance through 
the documents and regulations.  
‒ I would like to thank my colleagues and friends dr Jaanika Kuld, dr Oivi 
Uibo, dr Kristel Köbas, dr Sirje Mikkel and dr Eve Õiglane-Šlik for the long 
motivating talks, for their support and being there for me when I needed 
them. 
‒ The feeling of having other PhD students of the Department of Paediatrics 
by my side has been a great motivation to continue with my work. I also 
thank all the co-residents in Paediatrics for the warm fellow feeling and 
knowing that I can always rely on them.  
‒ I am really grateful to all the colleagues from the Department of Neurology 
of the Children’s Clinic: dr Inga Talvik, dr Ulvi Vaher, dr Aita Napa, dr Reet 
Rein, dr Eve Õiglane-Šlik, prof Emeritus Tiina Talvik and dr Anneli Kolk 
for their patience in the last six months when I was finishing my studies and 
therefore could not concentrate to my clinical work as much as I should have 
done.  
 
I am really lucky to have so many good friends by my side whose help has been 
indescribable. The seven years I spent on my studies contained many ups and 
downs and their moral support at bad times has helped me to get back at my feet 
and continue my work even if it sometimes seemed impossible. I will never 
forget their support and I count them all as a part of my extended family. 
‒ I am grateful to my great friend, co-resident and co-PhD student dr Piia Jõgi 
who has been by my side the whole seven years. I strongly appreciate the 
advice she has given me concerning the studies or the life in general. I feel 
deeply for the time and long talks we had while walking with our newborns.  
‒ I could not overrate the contribution of my beloved friends dr Reet Kitus, dr 
Reet Moor, dr Karit Reinson, dr Kati Toom and dr Triin Leinemann whose 
enthusiasm and belief in me during the years has been more than helpful. 
They have helped me to see that there is so much more in life besides work 
and studying and I appreciate it in a great amount.  
72 
‒ I feel really honored for the friendship of professor Emeritus Tiina Talvik 
who has never stopped believing in me and has motivated me to finish the 
work in every imaginable way. I am grateful for her opinions and also for 
the possibilities to get acquainted with my “new love in life” – paediatric 
neurology.  
‒ My fellow in life and also in my residency studies in the last few years has 
been a great friend of mine – dr Stella Lilles. Her everlasting positivity and 
laughter has been a great motivation in times when no sun was shining 
behind the clouds. She has been the one I can rely on and I appreciate it 
greatly. 
‒ I own a lot to dr Aleksandr Peet. He has been a great friend and support 
throughout the years. I really appreciate the good advice he has given me 
during my studies and during revision of the thesis. His wide knowledge 
concerning paediatric endocrinology and terminology but also the values of 
life has been a great help.  
‒ This work would never have been finished without the help of my great 
friend, teacher and mentor – associate professor Inga Talvik. She has 
motivated me the most by cheering me up and teaching me what it is that 
really matters in life. Through her wisdom and friendship she has always 
supported me and taught me to see every difficulty in life as a possibility of 
growing and learning. I admire her for that. I will never forget the 
discussions about what it is that makes some people shine and I hope that I 
someday can solve the mystery of that problem for myself.  
 
At most I have to give credit to my wonderful family who I love and cherish. 
Without their help, support and patience finishing the studies would have been 
impossible.  
‒ I feel deeply grateful for my parents – Ene and Aivar Kohtla for my 
upbringing and encouraging the curiosity in me that has resulted in my 
everlasting studies and in my feeling that I still do not have enough 
knowledge. They have supported my every step and choice I have made in 
my life and never left my side. They have been my support at all the hard 
times and they have felt happy for my succeeding. I love and admire them 
for that.  
‒ My baby sister Karita has been the sunshine in my life and she has always 
known how to make me laugh and cheer me up. I am very grateful for her 
for being a good friend and “big sister” to my daughter in times when I was 
too busy with my work. 
‒ I wish to address my gratitude to my parents in-law – Sirje and Jaan 
Noormets for helping to babysit Karola during her sick-days and my 
travelling. I appreciate it a lot.  
‒ At last but not least – my strongest appreciation, thankfulness and love 
belongs to my closest family. My husband Alo has been the rock in my life I 
can rely on. He has supported my every decision and never complained 
73 
when I have not had enough time for him. He has been the greatest father to 
my precious daughter and I love him for that very much. I would not have 
ever found the strength to finish this work without his everlasting support 
and belief in me. I feel obligated for my daughter Karola because I have not 
had enough time for her that she has needed during my studies. But she has 
been the meaning of my continuing and finishing the thesis regardless. With 
her love, passion and endless laughter she has motivated and encouraged me. 













Name:  Klari Noormets 
Date of birth:  04.04.1983 
Address: Department of Paediatrics, University of Tartu, 
Lunini Street 6, Tartu 51014, Estonia 
Phone:  +372 5215801 
E-mail:  klari.noormets@kliinikum.ee 
 
Education 
2010 – …  University of Tartu, Faculty of Medicine, residency in 
Paediatrics (since 2013 Paediatric Neurology) 
2007 – 2014  University of Tartu, Faculty of Medicine, PhD studies 
2001 – 2007  University of Tartu, Faculty of Medicine 
1997 – 2001 The German Gymnasium of Kadriorg 
1989 – 1997  Õismäe Grammar School 
 
Professional employment 
2010 – … Children’s Clinic of Tartu University Hospital, Resident 
physician 
2004 – 2007 Anaesthesiology and Intensive Care Clinic of Tartu University  
   Hospital, Assistant intensive care nurse 




2007 ABC course of Animal Experiments, Helsinki University, 
Helsinki, Finland (2-weeks course) 
2013 6th Eilat International Educational Course: Pharmacological 
Treatment of Epilepsy, Jerusalem, Israel (1-week course) 
2013 Basic Gaucher Training 2013, Amsterdam, The Netherlands (2-
days course) 
2013 Epilepsy Genetics Workshop and the Meeting of Young 
Researchers in Epileptology 2013, Sde Boker, Israel (4-days 
course) 
2014 EFNS/ENS Spring School for young Neurologists 2014, Stare 
Splavy, Czech Republic (4-days course) 
 
Scientific work 
5 publications and 12 oral or poster presentations at international scientific 
conferences (including annual ESPE conferences). 
The topics of my research activity have been endocrine disturbances in a 
Wfs1-deficient mouse model of Wolfram syndrome and genetics of epilepsy. 
117 
30
I am a member of Estonian Paediatric Association, Estonian Doctors 
Association, International Child Neurology Association and a board member of 
Estonian Child Neurology Association. 
 
List of publications 
‒ Noormets, K.; Kõks, S.; Ivask, M.; Aunapuu, M.; Arend, A.; Vasar, E.; 
Tillmann. V (2014). Energy metabolism and thyroid function of mice with 
deleted wolfram (Wfs1) gene. Experimental and Clinical Endocrinology of 
Diabetes 
‒ Kõks, S.; Soomets, U.; Plaas, M.; Terasmaa, A.; Noormets, K.; Till-
mann, V.; Vasar, E.; Fernandes, C.; Schalkwyk, LC. (2011). Hypothalamic 
gene expression profile indicates a reduction in G protein signaling in the 
Wfs1 mutant mice. Physiological genomics, 43, 1351–1358. 
‒ Noormets, K.; Kõks, S.; Muldmaa, M.; Mauring, L.; Vasar, E.; 
Tillmann, V. (2011). Sex Differences in the Development of Diabetes in 
Mice with Deleted Wolframin (Wfs1) Gene. Experimental and Clinical 
Endocrinology of Diabetes, 119(5), 271–275. 
‒ Kõks, S.; Soomets, U.; Paya-Cano, J.; Fernandes, C.; Luuk, H.; Plaas, M.; 
Terasmaa, A.; Tillmann, V.; Noormets, K.; Vasar, E.; Schalkwyk, LC. 
(2009). Wfs1 gene deletion causes growth retardation in mice and interferes 
with the growth hormone pathway. Physiological genomics, 37, 249–259. 
‒ Noormets, K.; Kõks, S.; Kavak, A.; Arend, A.; Aunapuu, M.;Keldrimaa, A.; 
Vasar, E.; Tillmann, V. (2009). Male mice with deleted Wolframin (Wfs1) 























Nimi:  Klari Noormets 
Sünniaeg: 04.04.1983 
Aadress: SA Tartu Ülikooli Kliinikum, Lastekliinik 
Lunini 6, Tartu 51014, Eesti 
Tel: +372 5215801 
E-post:  klari.noormets@kliinikum.ee 
 
Haridus 
2010 – …  Tartu Ülikool, Arstiteaduskond, lastehaiguste residentuur 
(alates 2013 spetsialiseerumine neuroloogia kõrvalerialale)  
2007 – 2014  Tartu Ülikool, Arstiteaduskond, doktorantuur  
2001 – 2007  Tartu Ülikool, Arstiteaduskond, arstiõpe  
1997 – 2001 Kadrioru Saksa Gümnaasium 
1989 – 1997  Õismäe Humanitaarkeskkool 
 
Teenistuskäik 
2010 – … SA Tartu Ülikooli Kliinikum, Lastekliinik, arst-resident 
2004 – 2007 SA Tartu Ülikooli Kliinikum, Anestesioloogia ja intensiivravi 
kliinik, Üldintensiivravi osakond, intensiivravi abiõde 
2002  Tallinna Lastehaigla, Vastsündinute osakond, õe abiline 
 
Erialane täiendus 
2007 “Loomkatsete ABC” Helsingi Ülikool, Helsingi, Soome 
2013 6. Eilati rahvusvaheline täiendkoolitus “Epilepsia farmako-
loogiline ravi” Jeruusalem, Iisrael (1-nädalane koolitus)  
2013 “Gaucheri tõve baaskoolitus 2013” Amsterdam, Holland 
2013 “Epilepsia geneetika õpituba ja noorte epieptoloogide 
teaduskohtumine 2013”, Sde Boker, Iisrael (4-päevane kursus) 
2014 “EFNS/ENS noorte neuroloogide kevadkool 2014”, Stare 
Splavy, Tšehhi vabariik (4-päevane koolitus) 
 
Teadustegevus 
5 teadusartiklit ja 12 suulist või posterettekannet rahvusvahelistel teadus-
konverentsidel (muuhulgas ka ESPE – Euroopa Laste-endokrinoloogide Seltsi 
iga-aastastel konvrentsidel). 
Minu peamisteks uurimisteemadeks on olnud endokriinhäired Wolframi 
sündroomi loommudelil – Wfs1 puudulikkusega hiirel ja epilepsia geneetika. 
Olen Eesti Lastearstide Seltsi, Eesti Arstide Liidu, Rahvusvahelise Laste-






‒ Noormets, K.; Kõks, S.; Ivask, M.; Aunapuu, M.; Arend, A.; Vasar, E.; 
Tillmann. V (2014). Energy metabolism and thyroid function of mice with 
deleted wolfram (Wfs1) gene. Experimental and Clinical Endocrinology of 
Diabetes 
‒ Kõks, S.; Soomets, U.; Plaas, M.; Terasmaa, A.; Noormets, K.; Till-
mann, V.; Vasar, E.; Fernandes, C.; Schalkwyk, LC. (2011). Hypothalamic 
gene expression profile indicates a reduction in G protein signaling in the 
Wfs1 mutant mice. Physiological genomics, 43, 1351–1358. 
‒ Noormets, K.; Kõks, S.; Muldmaa, M.; Mauring, L.; Vasar, E.; 
Tillmann, V. (2011). Sex Differences in the Development of Diabetes in 
Mice with Deleted Wolframin (Wfs1) Gene. Experimental and Clinical 
Endocrinology of Diabetes, 119(5), 271–275. 
‒ Kõks, S.; Soomets, U.; Paya-Cano, J.; Fernandes, C.; Luuk, H.; Plaas, M.; 
Terasmaa, A.; Tillmann, V.; Noormets, K.; Vasar, E.; Schalkwyk, LC. 
(2009). Wfs1 gene deletion causes growth retardation in mice and interferes 
with the growth hormone pathway. Physiological genomics, 37, 249–259. 
‒ Noormets, K.; Kõks, S.; Kavak, A.; Arend, A.; Aunapuu, M.; Keldri-
maa, A.; Vasar, E.; Tillmann, V. (2009). Male mice with deleted Wolframin 
(Wfs1) gene have reduced fertility. Reproductive biology and endo-







DISSERTATIONES MEDICINAE  
UNIVERSITATIS TARTUENSIS  
 1. Heidi-Ingrid Maaroos. The natural course of gastric ulcer in connection 
with chronic gastritis and Helicobacter pylori. Tartu, 1991. 
 2. Mihkel Zilmer. Na-pump in normal and tumorous brain tissues: Structu-
ral, functional and tumorigenesis aspects. Tartu, 1991. 
 3. Eero Vasar. Role of cholecystokinin receptors in the regulation of beha-
viour and in the action of haloperidol and diazepam. Tartu, 1992. 
 4. Tiina Talvik. Hypoxic-ischaemic brain damage in neonates (clinical, 
biochemical and brain computed tomographical investigation). Tartu, 1992. 
 5. Ants Peetsalu. Vagotomy in duodenal ulcer disease: A study of gastric 
acidity, serum pepsinogen I, gastric mucosal histology and Helicobacter 
pylori. Tartu, 1992. 
 6. Marika Mikelsaar. Evaluation of the gastrointestinal microbial ecosystem 
in health and disease. Tartu, 1992. 
 7. Hele Everaus. Immuno-hormonal interactions in chronic lymphocytic leu-
kaemia and multiple myeloma. Tartu, 1993. 
 8. Ruth Mikelsaar. Etiological factors of diseases in genetically consulted 
children and newborn screening: dissertation for the commencement of the 
degree of doctor of medical sciences. Tartu, 1993. 
 9. Agu Tamm. On metabolic action of intestinal microflora: clinical aspects. 
Tartu, 1993. 
 10. Katrin Gross. Multiple sclerosis in South-Estonia (epidemiological and 
computed tomographical investigations). Tartu, 1993. 
 11. Oivi Uibo. Childhood coeliac disease in Estonia: occurrence, screening, 
diagnosis and clinical characterization. Tartu, 1994. 
 12. Viiu Tuulik. The functional disorders of central nervous system of che-
mistry workers. Tartu, 1994. 
 13. Margus Viigimaa. Primary haemostasis, antiaggregative and anticoagulant 
treatment of acute myocardial infarction. Tartu, 1994. 
 14. Rein Kolk. Atrial versus ventricular pacing in patients with sick sinus 
syndrome. Tartu, 1994. 
 15. Toomas Podar. Incidence of childhood onset type 1 diabetes mellitus in 
Estonia. Tartu, 1994. 
 16. Kiira Subi. The laboratory surveillance of the acute respiratory viral 
infections in Estonia. Tartu, 1995. 
17. Irja Lutsar. Infections of the central nervous system in children (epidemi-
ologic, diagnostic and therapeutic aspects, long term outcome). Tartu, 1995. 
18. Aavo Lang. The role of dopamine, 5-hydroxytryptamine, sigma and 
NMDA receptors in the action of antipsychotic drugs. Tartu, 1995. 
19.  Andrus Arak. Factors influencing the survival of patients after radical 
surgery for gastric cancer. Tartu, 1996. 
20.  Tõnis Karki. Quantitative composition of the human lactoflora and 
method for its examination. Tartu, 1996. 
121
31
21. Reet Mändar. Vaginal microflora during pregnancy and its transmission 
to newborn. Tartu, 1996.  
22. Triin Remmel. Primary biliary cirrhosis in Estonia: epidemiology, clinical 
characterization and prognostication of the course of the disease. Tartu, 
1996. 
23. Toomas Kivastik. Mechanisms of drug addiction: focus on positive rein-
forcing properties of morphine. Tartu, 1996.  
24.  Paavo Pokk. Stress due to sleep deprivation: focus on GABAA receptor-
chloride ionophore complex. Tartu, 1996. 
25. Kristina Allikmets. Renin system activity in essential hypertension. As-
sociations with atherothrombogenic cardiovascular risk factors and with 
the efficacy of calcium antagonist treatment. Tartu, 1996. 
26. Triin Parik. Oxidative stress in essential hypertension: Associations with 
metabolic disturbances and the effects of calcium antagonist treatment. 
Tartu, 1996. 
27.  Svetlana Päi. Factors promoting heterogeneity of the course of rheumatoid 
arthritis. Tartu, 1997.  
28. Maarike Sallo. Studies on habitual physical activity and aerobic fitness in 
4 to 10 years old children. Tartu, 1997. 
29. Paul Naaber. Clostridium difficile infection and intestinal microbial eco-
logy. Tartu, 1997. 
30. Rein Pähkla. Studies in pinoline pharmacology. Tartu, 1997. 
31. Andrus Juhan Voitk. Outpatient laparoscopic cholecystectomy. Tartu, 1997. 
32. Joel Starkopf. Oxidative stress and ischaemia-reperfusion of the heart. 
Tartu, 1997. 
33.  Janika Kõrv. Incidence, case-fatality and outcome of stroke. Tartu, 1998. 
34. Ülla Linnamägi. Changes in local cerebral blood flow and lipid peroxida-
tion following lead exposure in experiment. Tartu, 1998. 
35. Ave Minajeva. Sarcoplasmic reticulum function: comparison of atrial and 
ventricular myocardium. Tartu, 1998. 
36. Oleg Milenin. Reconstruction of cervical part of esophagus by revascular-
ised ileal autografts in dogs. A new complex multistage method. Tartu, 
1998. 
37. Sergei Pakriev. Prevalence of depression, harmful use of alcohol and 
alcohol dependence among rural population in Udmurtia. Tartu, 1998. 
38. Allen Kaasik. Thyroid hormone control over -adrenergic signalling 
system in rat atria. Tartu, 1998. 
39. Vallo Matto. Pharmacological studies on anxiogenic and antiaggressive 
properties of antidepressants. Tartu, 1998. 
40. Maire Vasar. Allergic diseases and bronchial hyperreactivity in Estonian 
children in relation to environmental influences. Tartu, 1998. 
41. Kaja Julge. Humoral immune responses to allergens in early childhood. 
Tartu, 1998. 
42. Heli Grünberg. The cardiovascular risk of Estonian schoolchildren. 
A cross-sectional study of 9-, 12- and 15-year-old children. Tartu, 1998. 
122
43. Epp Sepp. Formation of intestinal microbial ecosystem in children. Tartu, 
1998. 
44. Mai Ots. Characteristics of the progression of human and experimental 
glomerulopathies. Tartu, 1998. 
45. Tiina Ristimäe. Heart rate variability in patients with coronary artery 
disease. Tartu, 1998. 
46. Leho Kõiv. Reaction of the sympatho-adrenal and hypothalamo-pituitary-
adrenocortical system in the acute stage of head injury. Tartu, 1998. 
47. Bela Adojaan. Immune and genetic factors of childhood onset IDDM in 
Estonia. An epidemiological study. Tartu, 1999. 
48. Jakov Shlik. Psychophysiological effects of cholecystokinin in humans. 
Tartu, 1999. 
49. Kai Kisand. Autoantibodies against dehydrogenases of -ketoacids. Tartu, 
1999. 
50. Toomas Marandi. Drug treatment of depression in Estonia. Tartu, 1999. 
51. Ants Kask. Behavioural studies on neuropeptide Y. Tartu, 1999. 
52. Ello-Rahel Karelson. Modulation of adenylate cyclase activity in the rat 
hippocampus by neuropeptide galanin and its chimeric analogs. Tartu, 1999. 
53. Tanel Laisaar. Treatment of pleural empyema — special reference to 
intrapleural therapy with streptokinase and surgical treatment modalities. 
Tartu, 1999. 
54. Eve Pihl. Cardiovascular risk factors in middle-aged former athletes. 
Tartu, 1999. 
55.  Katrin Õunap. Phenylketonuria in Estonia: incidence, newborn screening, 
diagnosis, clinical characterization and genotype/phenotype correlation. 
Tartu, 1999. 
56. Siiri Kõljalg. Acinetobacter – an important nosocomial pathogen. Tartu, 
1999. 
57. Helle Karro. Reproductive health and pregnancy outcome in Estonia: 
association with different factors. Tartu, 1999. 
58. Heili Varendi. Behavioral effects observed in human newborns during 
exposure to naturally occurring odors. Tartu, 1999.  
59. Anneli Beilmann. Epidemiology of epilepsy in children and adolescents in 
Estonia. Prevalence, incidence, and clinical characteristics. Tartu, 1999. 
60. Vallo Volke. Pharmacological and biochemical studies on nitric oxide in 
the regulation of behaviour. Tartu, 1999. 
61.  Pilvi Ilves. Hypoxic-ischaemic encephalopathy in asphyxiated term infants. 
A prospective clinical, biochemical, ultrasonographical study. Tartu, 1999. 
62. Anti Kalda. Oxygen-glucose deprivation-induced neuronal death and its 
pharmacological prevention in cerebellar granule cells. Tartu, 1999. 
63.  Eve-Irene Lepist. Oral peptide prodrugs – studies on stability and 
absorption. Tartu, 2000. 
64. Jana Kivastik. Lung function in Estonian schoolchildren: relationship 
with anthropometric indices and respiratory symptomas, reference values 
for dynamic spirometry. Tartu, 2000. 
123
65. Karin Kull. Inflammatory bowel disease: an immunogenetic study. Tartu, 
2000. 
66. Kaire Innos. Epidemiological resources in Estonia: data sources, their 
quality and feasibility of cohort studies. Tartu, 2000. 
67. Tamara Vorobjova. Immune response to Helicobacter pylori and its 
association with dynamics of chronic gastritis and epithelial cell turnover 
in antrum and corpus. Tartu, 2001. 
68. Ruth Kalda. Structure and outcome of family practice quality in the 
changing health care system of Estonia. Tartu, 2001. 
69. Annika Krüüner. Mycobacterium tuberculosis – spread and drug 
resistance in Estonia. Tartu, 2001. 
70. Marlit Veldi. Obstructive Sleep Apnoea: Computerized Endopharyngeal 
Myotonometry of the Soft Palate and Lingual Musculature. Tartu, 2001. 
71. Anneli Uusküla. Epidemiology of sexually transmitted diseases in Estonia 
in 1990–2000. Tartu, 2001. 
72. Ade Kallas. Characterization of antibodies to coagulation factor VIII. 
Tartu, 2002. 
73. Heidi Annuk. Selection of medicinal plants and intestinal lactobacilli as 
antimicrobil components for functional foods. Tartu, 2002.  
74. Aet Lukmann. Early rehabilitation of patients with ischaemic heart 
disease after surgical revascularization of the myocardium:  assessment of 
health-related quality of life, cardiopulmonary reserve and oxidative stress. 
A clinical study. Tartu, 2002. 
75. Maigi Eisen. Pathogenesis of Contact Dermatitis: participation of Oxida-
tive Stress. A clinical – biochemical study. Tartu, 2002. 
76. Piret Hussar. Histology of the post-traumatic bone repair in rats. Elabora-
tion and use of a new standardized experimental model – bicortical perfora-
tion of tibia compared to internal fracture and resection osteotomy. Tartu, 
2002. 
77. Tõnu Rätsep. Aneurysmal subarachnoid haemorrhage: Noninvasive moni-
toring of cerebral haemodynamics. Tartu, 2002. 
78. Marju Herodes. Quality of life of people with epilepsy in Estonia. Tartu, 
2003. 
79. Katre Maasalu. Changes in bone quality due to age and genetic disorders 
and their clinical expressions in Estonia. Tartu, 2003. 
80. Toomas Sillakivi. Perforated peptic ulcer in Estonia: epidemiology, risk 
factors and relations with Helicobacter pylori. Tartu, 2003. 
81. Leena Puksa. Late responses in motor nerve conduction studies. F and A 
waves in normal subjects and patients with neuropathies. Tartu, 2003. 
82. Krista Lõivukene. Helicobacter pylori in gastric microbial ecology and  
its antimicrobial susceptibility pattern. Tartu, 2003. 
83. Helgi Kolk. Dyspepsia and Helicobacter pylori infection: the diagnostic 
value of symptoms, treatment and follow-up of patients referred for upper 
gastrointestinal endoscopy by family physicians. Tartu, 2003. 
124 
84.  Helena Soomer. Validation of identification and age estimation methods 
in forensic odontology. Tartu, 2003. 
85. Kersti Oselin. Studies on the human MDR1, MRP1, and MRP2 ABC 
transporters: functional relevance of the genetic polymorphisms in the 
MDR1 and MRP1 gene. Tartu, 2003. 
86. Jaan Soplepmann. Peptic ulcer haemorrhage in Estonia: epidemiology, 
prognostic factors, treatment and outcome. Tartu, 2003. 
87. Margot Peetsalu. Long-term follow-up after vagotomy in duodenal ulcer 
disease: recurrent ulcer, changes in the function, morphology and Helico-
bacter pylori colonisation of the gastric mucosa. Tartu, 2003. 
88. Kersti Klaamas. Humoral immune response to Helicobacter pylori a 
study of host-dependent and microbial factors. Tartu, 2003. 
89. Pille Taba. Epidemiology of Parkinson’s disease in Tartu, Estonia. Pre-
valence, incidence, clinical characteristics, and pharmacoepidemiology. 
Tartu, 2003.  
90. Alar Veraksitš. Characterization of behavioural and biochemical pheno-
type of cholecystokinin-2 receptor deficient mice: changes in the function 
of the dopamine and endopioidergic system. Tartu, 2003. 
91. Ingrid Kalev. CC-chemokine receptor 5 (CCR5) gene polymorphism in 
Estonians and in patients with Type I and Type II diabetes mellitus. Tartu, 
2003. 
92. Lumme Kadaja. Molecular approach to the regulation of mitochondrial 
function in oxidative muscle cells. Tartu, 2003. 
93. Aive Liigant. Epidemiology of primary central nervous system tumours 
in Estonia from 1986 to 1996. Clinical characteristics, incidence, survival 
and prognostic factors. Tartu, 2004. 
94. Andres, Kulla. Molecular characteristics of mesenchymal stroma in 
human astrocytic gliomas. Tartu, 2004. 
95. Mari Järvelaid. Health damaging risk behaviours in adolescence. Tartu, 
2004. 
96. Ülle Pechter. Progression prevention strategies in chronic renal failure 
and hypertension. An experimental and clinical study. Tartu, 2004. 
97. Gunnar Tasa. Polymorphic glutathione S-transferases – biology and role 
in modifying genetic susceptibility to senile cataract and primary open 
angle glaucoma. Tartu, 2004. 
98. Tuuli Käämbre. Intracellular energetic unit: structural and functional 
aspects. Tartu, 2004. 
99.  Vitali Vassiljev. Influence of nitric oxide syntase inhibitors on the effects  
of ethanol after acute and chronic ethanol administration and withdrawal. 
Tartu, 2004. 
100. Aune Rehema. Assessment of nonhaem ferrous iron and glutathione 
redox ratio as markers of pathogeneticity of oxidative stress in different 
clinical groups. Tartu, 2004. 
101.   Evelin Seppet. Interaction of mitochondria and ATPases in oxidative 
muscle cells in normal and pathological conditions. Tartu, 2004. 
125 
32
102. Eduard Maron. Serotonin function in panic disorder: from clinical expe-
riments to brain imaging and genetics. Tartu, 2004.  
103. Marje Oona. Helicobacter pylori infection in children: epidemiological 
and therapeutic aspects. Tartu, 2004. 
104. Kersti Kokk. Regulation of active and passive molecular transport in the 
testis. Tartu, 2005.  
105. Vladimir Järv. Cross-sectional imaging for pretreatment evaluation and 
follow-up of pelvic malignant tumours. Tartu, 2005. 
106. Andre Õun. Epidemiology of adult epilepsy in Tartu, Estonia. Incidence, 
prevalence and medical treatment. Tartu, 2005. 
107. Piibe Muda. Homocysteine and hypertension: associations between 
homocysteine and essential hypertension in treated and untreated hyper-
tensive patients with and without coronary artery disease. Tartu, 2005. 
108. Külli Kingo. The interleukin-10 family cytokines gene polymorphisms in 
plaque psoriasis. Tartu, 2005.  
109. Mati Merila. Anatomy and clinical relevance of the glenohumeral joint  
capsule and ligaments. Tartu, 2005. 
110. Epp Songisepp. Evaluation of technological and functional properties of 
the new probiotic Lactobacillus fermentum ME-3. Tartu, 2005. 
111. Tiia Ainla. Acute myocardial infarction in Estonia: clinical characte-
ristics, management and outcome. Tartu, 2005. 
112. Andres Sell. Determining the minimum local anaesthetic requirements for 
hip replacement surgery under spinal anaesthesia – a study employing a 
spinal catheter. Tartu, 2005. 
113. Tiia Tamme. Epidemiology of odontogenic tumours in Estonia. Patho-
genesis and clinical behaviour of ameloblastoma. Tartu, 2005. 
114. Triine Annus. Allergy in Estonian schoolchildren: time trends and 
characteristics. Tartu, 2005. 
115. Tiia Voor. Microorganisms in infancy and development of allergy: com-
parison  of  Estonian  and Swedish  children. Tartu, 2005. 
116. Priit Kasenõmm. Indicators for tonsillectomy in adults with recurrent 
tonsillitis – clinical, microbiological and pathomorphological investi-
gations. Tartu, 2005. 
117. Eva Zusinaite. Hepatitis C virus: genotype identification and interactions 
between viral proteases. Tartu, 2005. 
118. Piret Kõll. Oral lactoflora in chronic periodontitis and periodontal health. 
Tartu, 2006. 
119. Tiina Stelmach. Epidemiology of cerebral palsy and unfavourable neuro-
developmental outcome in child population of Tartu city and county, 
Estonia Prevalence, clinical features and risk factors. Tartu, 2006. 
120. Katrin Pudersell. Tropane alkaloid production and riboflavine excretion 
in the field and tissue cultures of henbane (Hyoscyamus niger L.). Tartu, 
2006.  
121. Külli Jaako. Studies on the role of neurogenesis in brain plasticity. Tartu, 
2006.  
126 
122. Aare Märtson. Lower limb lengthening: experimental studies of bone 
regeneration and long-term clinical results. Tartu, 2006. 
123.  Heli Tähepõld. Patient consultation in family medicine. Tartu, 2006. 
124. Stanislav Liskmann. Peri-implant disease: pathogenesis, diagnosis and 
treatment in view of both inflammation and oxidative stress profiling. 
Tartu, 2006. 
125. Ruth Rudissaar. Neuropharmacology of atypical antipsychotics and an 
animal model of psychosis. Tartu, 2006. 
126. Helena Andreson. Diversity of Helicobacter pylori genotypes in 
Estonian patients with chronic inflammatory gastric diseases. Tartu, 2006. 
127. Katrin Pruus. Mechanism of action of antidepressants: aspects of sero-
toninergic system and its interaction with glutamate. Tartu, 2006. 
128. Priit Põder. Clinical and experimental investigation: relationship of 
ischaemia/reperfusion injury with oxidative stress in abdominal aortic 
aneurysm repair and in extracranial brain artery endarterectomy and possi-
bilities of protection against ischaemia using a glutathione analogue in a 
rat model of global brain ischaemia. Tartu, 2006.   
129. Marika Tammaru. Patient-reported outcome measurement in rheumatoid 
arthritis. Tartu, 2006. 
130.   Tiia Reimand. Down syndrome in Estonia. Tartu, 2006. 
131. Diva Eensoo. Risk-taking in traffic and Markers of Risk-Taking Beha-
viour in Schoolchildren and Car Drivers. Tartu, 2007. 
132. Riina Vibo. The third stroke registry in Tartu, Estonia from 2001 to 2003: 
incidence, case-fatality, risk factors and long-term outcome. Tartu, 2007.  
133. Chris Pruunsild. Juvenile idiopathic arthritis in children in Estonia. 
Tartu, 2007. 
134. Eve Õiglane-Šlik. Angelman and Prader-Willi syndromes in Estonia. 
Tartu, 2007. 
135. Kadri Haller. Antibodies to follicle stimulating hormone. Significance in 
female infertility. Tartu, 2007. 
136.  Pille Ööpik. Management of depression in family medicine. Tartu, 2007. 
137. Jaak Kals. Endothelial function and arterial stiffness in patients with 
atherosclerosis and in healthy subjects. Tartu, 2007. 
138.  Priit Kampus. Impact of inflammation, oxidative stress and age on 
arterial stiffness and carotid artery intima-media thickness. Tartu, 2007. 
139.  Margus Punab. Male fertility and its risk factors in Estonia. Tartu, 2007. 
140. Alar Toom. Heterotopic ossification after total hip arthroplasty: clinical 
and pathogenetic investigation. Tartu, 2007. 
141. Lea Pehme. Epidemiology of tuberculosis in Estonia 1991–2003 with 
special regard to extrapulmonary tuberculosis and delay in diagnosis of 
pulmonary tuberculosis. Tartu, 2007. 
142.  Juri Karjagin. The pharmacokinetics of metronidazole and meropenem 
in septic shock. Tartu, 2007. 
143. Inga Talvik. Inflicted traumatic brain injury shaken baby syndrome in 
Estonia – epidemiology and outcome. Tartu, 2007. 
127 
144.  Tarvo Rajasalu. Autoimmune diabetes: an immunological study of type 
1 diabetes in humans and in a model of experimental diabetes (in RIP-
B7.1 mice). Tartu, 2007. 
145. Inga Karu. Ischaemia-reperfusion injury of the heart during coronary 
surgery: a clinical study investigating the effect of hyperoxia. Tartu, 2007. 
146. Peeter Padrik. Renal cell carcinoma: Changes in natural history and 
treatment of metastatic disease. Tartu, 2007.  
147.  Neve Vendt. Iron deficiency and iron deficiency anaemia in infants aged 
9 to 12 months in Estonia. Tartu, 2008.  
148. Lenne-Triin Heidmets. The effects of neurotoxins on brain plasticity: 
focus on neural Cell Adhesion Molecule. Tartu, 2008. 
149.  Paul Korrovits. Asymptomatic inflammatory prostatitis: prevalence, etio-
logical factors, diagnostic tools. Tartu, 2008. 
150.   Annika Reintam. Gastrointestinal failure in intensive care patients. Tartu, 
2008. 
151.   Kristiina Roots. Cationic regulation of Na-pump in the normal, Alzhei-
mer’s and CCK2 receptor-deficient brain. Tartu, 2008. 
152. Helen Puusepp. The genetic causes of mental retardation in Estonia: 
fragile X syndrome and creatine transporter defect. Tartu, 2009. 
153. Kristiina Rull. Human chorionic gonadotropin beta genes and recurrent 
miscarriage: expression and variation study. Tartu, 2009. 
154.  Margus Eimre. Organization of energy transfer and feedback regulation 
in oxidative muscle cells. Tartu, 2009. 
155. Maire Link. Transcription factors FoxP3 and AIRE: autoantibody 
associations. Tartu, 2009. 
156.  Kai Haldre. Sexual health and behaviour of young women in Estonia. 
Tartu, 2009. 
157. Kaur Liivak. Classical form of congenital adrenal hyperplasia due to  
21-hydroxylase deficiency in Estonia: incidence, genotype and phenotype 
with special attention to short-term growth and 24-hour blood pressure. 
Tartu, 2009. 
158. Kersti Ehrlich. Antioxidative glutathione analogues (UPF peptides) – 
molecular design, structure-activity relationships and testing the protec-
tive properties. Tartu, 2009. 
159. Anneli Rätsep. Type 2 diabetes care in family medicine. Tartu, 2009. 
160. Silver Türk. Etiopathogenetic aspects of chronic prostatitis: role of 
mycoplasmas, coryneform bacteria and oxidative stress. Tartu, 2009. 
161. Kaire Heilman. Risk markers for cardiovascular disease and low bone 
mineral density in children with type 1 diabetes. Tartu, 2009. 
162.  Kristi Rüütel. HIV-epidemic in Estonia: injecting drug use and quality of 
life of people living with HIV. Tartu, 2009. 
163. Triin Eller. Immune markers in major depression and in antidepressive 
treatment. Tartu, 2009. 
128
164.  Siim Suutre. The role of TGF-β isoforms and osteoprogenitor cells in the 
pathogenesis of heterotopic ossification. An experimental and clinical 
study of hip arthroplasty. Tartu, 2010. 
165.  Kai Kliiman. Highly drug-resistant tuberculosis in Estonia: Risk factors 
and predictors of poor treatment outcome. Tartu, 2010.  
166.  Inga Villa. Cardiovascular health-related nutrition, physical activity and 
fitness in Estonia. Tartu, 2010. 
167. Tõnis Org. Molecular function of the first PHD finger domain of Auto-
immune Regulator protein. Tartu, 2010.  
168. Tuuli Metsvaht. Optimal antibacterial therapy of neonates at risk of early 
onset sepsis. Tartu, 2010. 
169.  Jaanus Kahu. Kidney transplantation: Studies on donor risk factors and 
mycophenolate mofetil. Tartu, 2010.  
170.  Koit Reimand. Autoimmunity in reproductive failure: A study on as-
sociated autoantibodies and autoantigens. Tartu, 2010. 
171. Mart Kull. Impact of vitamin D and hypolactasia on bone mineral 
density: a population based study in Estonia. Tartu, 2010. 
172. Rael Laugesaar. Stroke in children – epidemiology and risk factors. 
Tartu, 2010.  
173.  Mark Braschinsky. Epidemiology and quality of life issues of hereditary 
spastic paraplegia in Estonia and implemention of genetic analysis in 
everyday neurologic practice. Tartu, 2010. 
174. Kadri Suija. Major depression in family medicine: associated factors, 
recurrence and possible intervention. Tartu, 2010. 
175. Jarno Habicht. Health care utilisation in Estonia: socioeconomic determi-
nants and financial burden of out-of-pocket payments. Tartu, 2010. 
176. Kristi Abram. The prevalence and risk factors of rosacea. Subjective 
disease perception of rosacea patients. Tartu, 2010. 
177. Malle Kuum. Mitochondrial and endoplasmic reticulum cation fluxes: 
Novel roles in cellular physiology. Tartu, 2010. 
178. Rita Teek. The genetic causes of early onset hearing loss in Estonian 
children. Tartu, 2010. 
179. Daisy Volmer. The development of community pharmacy services in 
Estonia – public and professional perceptions 1993–2006. Tartu, 2010. 
180. Jelena Lissitsina. Cytogenetic causes in male infertility. Tartu, 2011. 
181.  Delia Lepik. Comparison of gunshot injuries caused from Tokarev, 
Makarov and Glock 19 pistols at different firing distances. Tartu, 2011. 
182.  Ene-Renate Pähkla. Factors related to the efficiency of treatment of 
advanced periodontitis. Tartu, 2011.  
183. Maarja Krass. L-Arginine pathways and antidepressant action. Tartu, 
2011.  
184.  Taavi Lai. Population health measures to support evidence-based  
health policy in Estonia. Tartu, 2011.  
129
33
185. Tiit Salum. Similarity and difference of temperature-dependence of the 
brain sodium pump in normal, different neuropathological, and aberrant 
conditions and its possible reasons. Tartu, 2011.  
186.  Tõnu Vooder. Molecular differences and similarities between histo-
logical subtypes of non-small cell lung cancer. Tartu, 2011.  
187.  Jelena Štšepetova. The characterisation of intestinal lactic acid bacteria 
using bacteriological, biochemical and molecular approaches. Tartu, 2011.  
188. Radko Avi. Natural polymorphisms and transmitted drug resistance in 
Estonian HIV-1 CRF06_cpx and its recombinant viruses. Tartu, 2011, 116 p. 
189.  Edward Laane. Multiparameter flow cytometry in haematological malig-
nancies. Tartu, 2011, 152 p. 
190.  Triin Jagomägi. A study of the genetic etiology of nonsyndromic cleft lip 
and palate. Tartu, 2011, 158 p. 
191.  Ivo Laidmäe. Fibrin glue of fish (Salmo salar) origin: immunological 
study and development of new pharmaceutical preparation. Tartu, 2012, 
150 p. 
192.  Ülle Parm. Early mucosal colonisation and its role in prediction of inva-
sive infection in neonates at risk of early onset sepsis. Tartu, 2012, 168 p. 
193.  Kaupo Teesalu. Autoantibodies against desmin and transglutaminase 2 in 
celiac disease: diagnostic and functional significance. Tartu, 2012, 142 p. 
194. Maksim Zagura. Biochemical, functional and structural profiling of 
arterial damage in atherosclerosis. Tartu, 2012, 162 p. 
195. Vivian Kont. Autoimmune regulator: characterization of thymic gene 
regulation and promoter methylation. Tartu, 2012, 134 p. 
196. Pirje Hütt. Functional properties, persistence, safety and efficacy of 
potential probiotic lactobacilli. Tartu, 2012, 246 p. 
197.  Innar Tõru. Serotonergic modulation of CCK-4- induced panic. Tartu, 
2012, 132 p. 
198.  Sigrid Vorobjov. Drug use, related risk behaviour and harm reduction 
interventions utilization among injecting drug users in Estonia: impli-
cations for drug policy. Tartu, 2012, 120 p. 
199.  Martin Serg. Therapeutic aspects of central haemodynamics, arterial 
stiffness and oxidative stress in hypertension. Tartu, 2012, 156 p.  
200. Jaanika Kumm. Molecular markers of articular tissues in early knee 
osteoarthritis: a population-based longitudinal study in middle-aged sub-
jects. Tartu, 2012, 159 p. 
201. Kertu Rünkorg. Functional changes of dopamine, endopioid and endo-
cannabinoid systems in CCK2 receptor deficient mice. Tartu, 2012, 125 p. 
202. Mai Blöndal. Changes in the baseline characteristics, management and 
outcomes of acute myocardial infarction in Estonia. Tartu, 2012, 127 p.        
203. Jana Lass. Epidemiological and clinical aspects of medicines use in 
children in Estonia. Tartu, 2012, 170 p. 
204. Kai Truusalu. Probiotic lactobacilli in experimental persistent Salmo-
nella infection. Tartu, 2013, 139 p.  
130
205. Oksana Jagur.  Temporomandibular joint diagnostic imaging in relation 
to pain and bone characteristics. Long-term results of arthroscopic treat-
ment. Tartu, 2013, 126 p. 
206. Katrin Sikk. Manganese-ephedrone intoxication – pathogenesis of neuro-
logical damage and clinical symptomatology. Tartu, 2013, 125 p. 
207. Kai Blöndal. Tuberculosis in Estonia with special emphasis on drug-
resistant tuberculosis: Notification rate, disease recurrence and mortality. 
Tartu, 2013, 151 p. 
208. Marju Puurand. Oxidative phosphorylation in different diseases of 
gastric mucosa. Tartu, 2013, 123 p.  
209. Aili Tagoma. Immune activation in female infertility: Significance of 
autoantibodies and inflammatory mediators. Tartu, 2013, 135 p. 
210.  Liis Sabre. Epidemiology of traumatic spinal cord injury in Estonia. 
Brain activation in the acute phase of traumatic spinal cord injury. Tartu, 
2013, 135 p. 
211. Merit Lamp. Genetic susceptibility factors in endometriosis. Tartu, 2013, 
125 p. 
212.  Erik Salum. Beneficial effects of vitamin D and angiotensin II receptor 
blocker on arterial damage. Tartu, 2013, 167 p.   
213.  Maire Karelson. Vitiligo: clinical aspects, quality of life and the role of 
melanocortin system in pathogenesis. Tartu, 2013, 153 p.  
214. Kuldar Kaljurand. Prevalence of exfoliation syndrome in Estonia and its 
clinical significance. Tartu, 2013, 113 p.  
215.  Raido Paasma. Clinical study of methanol poisoning: handling large out-
breaks, treatment with antidotes, and long-term outcomes. Tartu, 2013,  
96 p. 
216.  Anne Kleinberg. Major depression in Estonia: prevalence, associated 
factors, and use of health services. Tartu, 2013, 129 p. 
217.  Triin Eglit. Obesity, impaired glucose regulation, metabolic syndrome 
and their associations with high-molecular-weight adiponectin levels. 
Tartu, 2014, 115 p. 
218.  Kristo Ausmees. Reproductive function in middle-aged males: Asso-
ciations with prostate, lifestyle and couple infertility status. Tartu, 2014, 
125 p.  
219.  Kristi Huik. The influence of host genetic factors on the susceptibility to 
HIV and HCV infections among intravenous drug users. Tartu, 2014, 
144 p.  
220. Liina Tserel. Epigenetic profiles of monocytes, monocyte-derived macro-
phages and dendritic cells. Tartu, 2014, 143 p. 
221. Irina Kerna. The contribution of ADAM12 and CILP genes to the 
development of knee osteoarthritis. Tartu, 2014, 152 p. 
222. Ingrit Liiv. Autoimmune regulator protein interaction with DNA-depen-
dent protein kinase and its role in apoptosis. Tartu, 2014, 143 p. 
223.  Liivi Maddison. Tissue perfusion and metabolism during intra-abdominal 
hypertension. Tartu, 2014, 103 p. 
131
224.  Krista Ress. Childhood coeliac disease in Estonia, prevalence in atopic 
dermatitis and immunological characterisation of coexistence. Tartu, 
2014, 124 p. 
225.  Kai Muru. Prenatal screening strategies, long-term outcome of children 
with marked changes in maternal screening tests and the most common 
syndromic heart anomalies in Estonia. Tartu, 2014, 189 p. 
226. Kaja Rahu. Morbidity and mortality among Baltic Chernobyl cleanup 
workers: a register-based cohort study. Tartu, 2014, 155 p.  
